338 Interactions at the cell membrane and pathways of internalization of nano - sized materials for nanomedicine Valentina Francia ‡ , Daphne Montizaan ‡ and Anna Salvati * Review Open Access Address : Groningen Research Institute of Pharmacy , University of Groningen , 9713AV Groningen , Netherlands Email : Anna Salvati * - a . salvati @ rug . nl * Corresponding author ‡ Equal contributors Keywords : cell receptors ; drug targeting ; endocytosis ; nanoparticle corona ; nanoparticle uptake Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . doi : 10 . 3762 / bjnano . 11 . 25 Received : 30 September 2019 Accepted : 27 January 2020 Published : 14 February 2020 This article is part of the thematic issue " Engineered nanomedicines for advanced therapies " . Guest Editor : F . Baldelli Bombelli © 2020 Francia et al . ; licensee Beilstein - Institut . License and terms : see end of document . Abstract Nano - sized materials have great potential as drug carriers for nanomedicine applications . Thanks to their size , they can exploit the cellular machinery to enter cells and be trafficked intracellularly , thus they can be used to overcome some of the cellular barriers to drug delivery . Nano - sized drug carriers of very different properties can be prepared , and their surface can be modified by the addi - tion of targeting moieties to recognize specific cells . However , it is still difficult to understand how the material properties affect the subsequent interactions and outcomes at cellular level . As a consequence of this , designing targeted drugs remains a major chal - lenge in drug delivery . Within this context , we discuss the current understanding of the initial steps in the interactions of nano - sized materials with cells in relation to nanomedicine applications . In particular , we focus on the difficult interplay between the initial adhesion of nano - sized materials to the cell surface , the potential recognition by cell receptors , and the subsequent mechanisms cells use to internalize them . The factors affecting these initial events are discussed . Then , we briefly describe the different path - ways of endocytosis in cells and illustrate with some examples the challenges in understanding how nanomaterial properties , such as size , charge , and shape , affect the mechanisms cells use for their internalization . Technical difficulties in characterizing these mechanisms are presented . A better understanding of the first interactions of nano - sized materials with cells will help to design nanomedicines with improved targeting . 338 Introduction Nano - sized materials are widely studied in nanomedicine for their potential use as drug carriers , in imaging , and for diagnostic purposes [ 1 - 3 ] . Because of their size , they can interact with cells in similar ways as other nano - sized objects , such as proteins , cholesterol particles , and virus particles . These natural nano - sized objects are usually recognized by specific cell receptors at the plasma membrane and they are internalized by cells using the cell endocytic machinery [ 4 ] . Similarly , engineered nano - sized materials can exploit the cellular ma - chinery to be internalized by cells . In fact , since the cell mem - Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 339 brane blocks diffusion of complexes larger than ca . 1 kDa , nano - sized materials , such as nanomedicines , are transported into cells using energy - dependent mechanisms , unlike many small drugs currently present on the market [ 5 ] . This enables nanomedicines to potentially overcome problems associated with the passive diffusion of small molecular drugs through cell membranes , such as their indiscriminate internalization in dif - ferent cell types and organs , which is often associated with side effects [ 6 ] . Additionally , nanomedicines can encapsulate differ - ent types of hydrophilic and hydrophobic drugs , and they can be designed to control their release profile [ 7 ] . Several other char - acteristics of nanomaterials such as size , material , shape , sur - face charge , hydrophobicity , roughness , and elasticity can be tailored in order to meet various needs [ 3 , 8 ] . This high engin - eering potential can be exploited to control the distribution and behaviour of nanomedicines in biological environments . By tuning nanomedicine design , parameters such as serum – protein interactions , sequestration by the immune system , blood circu - lation time , biodistribution , and cellular recognition and intern - alization can be tailored [ 1 - 3 , 7 , 8 ] . Moreover , the surface of nanomedicines can be engineered by introducing functional groups to reduce clearance and increase biodistribution , as well as for active targeting purposes [ 1 , 2 , 9 , 10 ] . In fact , nanomedi - cines can be engineered to interact with specific cell receptors , opening up new strategies for targeting specific cell types and organs [ 9 - 12 ] . Despite this high engineering potential , active targeting remains one of the major challenges for nanomedi - cine success [ 13 , 14 ] , and so far only few targeted nanomedi - cines are currently present in the market , even if several are in clinical trials [ 6 ] . Recent advances in the field have shown the complexity of achieving targeted uptake by specific cells . For example , it has been shown that the biomolecules adsorbing on the nanoparti - cles once they are introduced in biological environments and the resulting corona can screen the targeting moieties [ 15 , 16 ] . At the same time , it has emerged that the corona itself can be recognized by receptors at the cell membrane [ 17 , 18 ] and that this initial recognition can affect the mechanism that cells use for the internalization of the nanoparticles [ 18 ] . However , several aspects of the initial recognition of nano - sized materials by cell receptors and of the molecular mechanisms leading to their uptake and intracellular processing are still unclear [ 19 - 21 ] . A better understanding of these processes can help to design smarter nanomedicines and to achieve better targeting [ 22 ] . Within this context , in this review we will summarise the cur - rent understanding of the very first steps of the interactions of nano - sized materials with cells , with a particular focus on the initial recognition at the cell membrane and the following Figure 1 : Interaction of nano - sized materials at the cell surface . First , nanoparticles adhere at the plasma membrane ( A ) and / or are recog - nized by cell receptors . Recognition can be achieved via targeting moieties , in the case of targeted nanomedicines ( B ) but also via the biomolecular corona ( C ) [ 10 , 11 , 17 , 18 ] . Secondly , nano - sized objects are internalized via various mechanisms ( here illustrated by different shapes in the cell membrane or a membrane protrusion ) . However , we do not know yet how nanomaterial properties ( such as size , shape , charge , as illustrated in the figure ) affect or determine the mechanism cells use for the internalization [ 7 , 19 - 22 ] . mechanisms of internalization by cells . We discuss these aspects in relation to the application of nano - sized materials for nanomedicine . Challenges in characterizing these first events will be illustrated , together with a brief description of the known endocytic pathways in cells . Review 1 Interactions of nano - sized materials at the cell surface and recognition by cell receptors 1 . 1 Active targeting The first steps in nanoparticle – cell interactions are those happening at the cell surface , including the adhesion of nano - particles to the cell membrane and the potential interaction with cell receptors ( Figure 1 ) . In order to control and affect these first events , nano - sized carriers can be modified with targeting moieties , such as peptides , proteins , or antibodies to specific - ally recognize receptors on the cell surface to achieve active Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 340 targeting [ 9 - 12 ] . These surface - functionalized nanomaterials should be internalized preferentially by cells that overexpress the targeted receptors . Examples of targeting moieties often exploited in nanomedicine are transferrin and folate , which target tumour cells overexpressing the corresponding receptors [ 23 , 24 ] , or hyaluronic acid , which directs nanocarriers to CD44 - overexpressing tumour cells [ 25 ] , among many others . While many new targeted nanomedicines are developed , just few of them are currently present on the market [ 6 ] . In fact , achieving efficient targeting in vivo remains a crucial challenge for drug delivery and recently the debate on the success of nanomedi - cine for delivering drugs to their target has been very active [ 26 - 28 ] . Indeed , it is difficult to design nanoparticles that achieve specif - ic targeting [ 7 , 9 , 29 ] . This is not only because a better under - standing of the factors controlling the very first interactions of nano - sized materials with live cells is still needed ( as we discuss here ) , but also because of challenges related to nanopar - ticle design and presentation of the targeting moiety . For instance , chemical coupling can affect the binding affinity of the targeting ligand to its receptor [ 30 ] . Moreover , it is difficult to control the targeting ligand density and its orientation . Both factors are important for the recognition by cell receptors and can affect cellular uptake [ 31 , 32 ] . Several reviews have summa - rized these and other similar challenges in the surface functio - nalization of nano - sized drug carriers to achieve targeting [ 33 - 35 ] . Ideally , by better controlling the early interactions with cells , nanomedicines should be recognized by the desired recep - tors and be trafficked intracellularly to their target . 1 . 2 Corona formation Another complication in achieving targeting is the formation of the biomolecular corona . When a nanomedicine ( or any nano - sized material ) comes in contact with a biological environment ( for example , blood , interstitial fluids , or extracellular matrices ) after administration , its surface is rapidly covered by various biomolecules leading to the formation of a corona [ 36 - 39 ] . It has been shown that , in some cases , the presence of the corona can mask the targeting moieties grafted on the nanoparticle sur - face , preventing recognition by cell receptors [ 15 , 16 , 40 ] . Corona formation can affect not only the targeting ability , but also particle size , stability , and overall surface properties [ 36 ] . Recent guidelines have started to highlight the importance of testing nanomedicines in the presence of relevant biological media in order to take corona effects into account [ 41 ] . Several strategies have been developed to try to reduce protein adsorption and corona formation . This can be achieved for instance by grafting hydrophilic polymers such as polyethylene glycol ( PEG ) on the surface of nanomedicines , or by introdu - cing zwitterionic modifications to make nanomaterials almost neutral [ 42 - 45 ] . These modifications reduce the amount of bio - molecules bound on the surface of nanomedicines after admin - istration ( though it has been shown that PEGylated surfaces can still adsorb proteins [ 46 , 47 ] ) and usually also lead to decreased uptake by cells . At the same time , the corona confers a new biological identity to nanomaterials and can affect the way nanomedicines are recognized and processed by cells [ 3 , 7 , 8 , 20 , 21 , 36 , 48 ] . Biomol - ecules present in the corona can , per se , have targeting capabil - ities towards particular receptors [ 17 , 18 , 49 - 52 ] . For example , apolipoprotein B and immunoglobulin G in the corona of 100 nm silica nanoparticles incubated with human serum were found to interact with their corresponding receptors , low - densi - ty lipoprotein receptor and Fc - gamma receptor I , respectively [ 17 ] . Similarly , lipid nanoparticles were efficiently targeted to the hepatocytes upon adsorption of apoE on their surface following administration [ 52 , 53 ] . Thus , controlling the corona composition can possibly provide new ways to control the initial interactions of nano - sized materials with cells . The corona composition depends on nanoparticle physicochem - ical characteristics , such as size , shape , charge , hydrophobicity , rigidity and surface characteristics [ 3 , 7 , 8 , 48 , 54 ] . By changing these properties , the corona composition might be tuned to contain components that bind to specific cell surface receptors and initiate internalization [ 17 , 49 , 55 - 57 ] . Similarly , artificial coronas can be formed to achieve recognition by specific recep - tors . For instance , Tonigold and colleagues have shown that pre - adsorbed antibodies , which could be seen as a form of pre - formed corona , kept , at least partially , their targeting ability in the presence of serum [ 40 ] . From a broader perspective , the effects of the corona on the interactions of nanoparticles with cells are being more and more recognized [ 41 , 58 , 59 ] . For example , multiple attempts have been made in trying to predict how the presence of the corona affects targeting of nanomedicines [ 60 , 61 ] . Similarly , it is known that the corona composition changes not only with nano - particle properties [ 3 , 7 , 8 , 48 , 54 ] , but also depending on serum origin [ 62 , 63 ] , serum preparation [ 63 - 65 ] , serum concentration [ 18 , 66 , 67 ] or health status [ 68 , 69 ] . However , many more facets of corona effects on nanoparticle – cell interactions still need to be understood , and even more so if one aims to exploit the corona for targeting . Similarly , how receptor interactions affect the subsequent inter - nalisation is also not known . Nano - sized materials and nanomedicines may interact only with one type of receptor ( Figure 2A ) or with multiple receptors at the same time Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 341 Figure 2 : Scheme of possible scenarios that can occur at the cell surface , resulting in nanoparticle uptake . Nanoparticles or their corona can be recognized by one ( A ) or multiple types of receptors ( B ) , and the recognition by receptors triggers nanoparticle uptake . Alternatively , the adhesion of the nanoparticle to the cell surface may induce internalization without receptor engagement ( C ) or the receptor is only involved in the initial adhesion of the nanoparticle , then uptake is triggered by different mechanisms , possibly induced by the nanoparticle itself ( D ) . ( Figure 2B ) , and the recognition by cell receptors triggers uptake . It might be that only high - affinity interactions contrib - ute to the entry , or that internalization occurs after receptor clustering . Alternatively , internalization may happen without recognition by specific receptors ( often referred to as unspe - cific binding and unspecific uptake ) , possibly triggered by the nano - sized object itself ( Figure 2C ) . Another possibility is that the recognition by cell receptors is involved only in the initial adhesion to the cell membrane , but not in the internalization ( Figure 2D ) . A combination of all these different possibilities may as well be present . In all cases , addressing these open ques - tions relative to the first interactions at the cell surface is re - quired to understand how to achieve a more efficient targeting of nanomedicines . 2 Internalization After the very first interactions at the plasma membrane , most nano - sized materials are internalized by cells [ 19 - 22 ] . Many questions are still open on how the initial interactions at the cell membrane affect the mechanisms cells use for the subsequent internalization . For instance , does receptor recognition trigger internalization via the same pathway used for its physiological ligands ? Or do the receptors mediate just the initial adhesion and is it the nano - sized material itself that triggers its own internalization , perhaps by other ways ( as also illustrated in Figure 2D ) ? How are uptake efficiency and the mechanisms of internalization modulated by the type of receptor engaged and / or by the initial interactions at the cell membrane ? These are ex - amples of the many questions that the field needs to address in order to control nanomedicine design to achieve the desired outcomes at cell level . In the following sections , we will summarize key aspects of the main mechanisms of cellular internalization , i . e . , endocytosis . Then , examples of works trying to understand how nanomateri - al properties affect the mechanisms of uptake by cells are presented to illustrate the complexity of outcomes observed and the difficulties in drawing conclusions . 2 . 1 Pathways of endocytosis in cells Cells developed several mechanisms of endocytosis in order to select and sort different cargoes to their intracellular destina - tion [ 70 , 71 ] . Although these mechanisms differ strongly , they also share a series of common features . As discussed by Johannes and colleagues [ 72 , 73 ] , common features required for uptake to occur are ( Figure 3 ) : • a specific lipid composition of the cell membrane at the site of endocytosis ( such as the presence of sphingol - ipids or cholesterol ) [ 70 , 72 , 74 - 76 ] , • cargo recognition at the cell membrane ( receptor - medi - ated or not ) and capture ( into coated vesicles or specific carriers ) [ 72 , 73 ] , • membrane bending , which occurs through different mechanisms , including the insertion of hydrophobic protein motifs in the membrane , local recruitment of membrane - bending domains , or scaffolding by proteins ( the classic example being clathrin ) [ 72 , 73 , 77 , 78 ] , and • scission of the endocytic vesicle , which can be guided by actin , dynamin and / or other proteins [ 79 - 83 ] . The specific details of each of these steps in the various endocytic mechanisms are extensively discussed in different excellent and specialized reviews [ 70 , 71 ] , including some focused on the mechanisms of endocytosis of nanomedicines [ 19 , 21 , 22 , 85 , 86 ] . Here , we briefly summarize some of their key aspects . Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 342 Figure 3 : Common features of endocytic pathways [ 73 ] . Endocytosis requires a specific cell membrane composition at the site of uptake ( A ) [ 72 , 74 - 76 ] and starts with the recognition of the cargo at the cell membrane ( B ) . Subsequently , membrane bending takes place to form a vesicle ( C ) [ 72 , 73 , 77 , 78 , 84 ] . Lastly , the vesicle is cleaved from the cell membrane via different mechanisms , which can involve various cellular components ( e . g . , actin and dynamin , here depicted as lines and circles , respectively ) ( D ) [ 79 , 80 ] . One of the most studied endocytic mechanism is clathrin - medi - ated endocytosis ( CME ) . CME is a form of receptor - mediated endocytosis that is used for the internalization of various bio - molecules among which low density lipoprotein for cholesterol uptake and transferrin for iron uptake . After binding of the ligand to its receptor , clathrin , the main actor in CME , is recruited at the cell membrane together with several other pro - teins and assembles around the forming vesicle to form a clathrin - coated pit . The GTP - binding protein dynamin is then required for the scission of the clathrin - coated pit to form an endocytic vesicle . Although it was thought to be non - essential for CME [ 87 ] , there are indications suggesting that actin fila - ments are also involved in the scission [ 88 , 89 ] and especially in the uptake of larger objects [ 90 ] via this pathway . Next to CME , several clathrin - independent endocytic ( CIE ) pathways have been described [ 71 , 91 , 92 ] . One of these path - ways is macropinocytosis , which cells use to internalize larger volumes of extracellular fluids and solutes . In macropinocyt - osis , extracellular fluids are engulfed by membrane ruffles and protrusions . Formation of these ruffles requires actin nucleation and in some cells also cholesterol [ 93 , 94 ] . Another frequently studied clathrin - independent pathway is the so - called caveolae - mediated endocytosis . Caveolae are 50 – 80 nm sized cup - shaped invaginations of the plasma membrane , consisting of lipid rafts enriched in cholesterol and sphingolipids , and coated with caveolins [ 95 - 97 ] . Endocytosis of these invaginations can be both receptor - dependent and - independent and requires actin and dynamin [ 96 , 98 , 99 ] . Nevertheless , the role of caveolae in endocytosis is currently being debated . Some suggest that caveolae are involved in transcytosis in endothelial cells [ 100 ] . According to this hypothesis , caveolae rapidly detach from the apical side of the membrane and fuse with the basal one , or directly form transient pores in thin endothelial cells [ 101 ] . Other studies have shown that in many cell types caveolae are normally not involved in endocytosis , but are stable invaginations present at the cell surface [ 102 , 103 ] , and only undergo endocytosis upon stimulation [ 96 , 104 ] . Apart from these mechanisms , phagocytosis is a form of recep - tor - mediated endocytosis of large particles ( above 0 . 5 µm ) , which requires the involvement of the cytoskeleton for mem - brane rearrangements . Professional phagocytic cells of the immune system use it to internalize pathogens [ 105 ] . However , it has emerged that also non - specialized phagocytic cells can internalize large particles [ 71 , 106 ] . Finally , other clathrin - independent endocytic mechanisms have been described . These include pathways mediated by flotillins , ADP - ribosylation factor 6 , endophilins , or tubular structures called clathrin - independent carriers ( CLICs ) . The exact machin - ery involved in these various clathrin - independent pathways is still investigated and the involvement of components like actin , cholesterol , or dynamin is often debated [ 71 , 91 , 92 ] . Overall , endocytosis is highly complex and still a very active field of research . This is one of the factors which makes the characterization of the mechanisms by which nano - sized mate - rials enter cells challenging . Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 343 2 . 2 Endocytosis of nanoparticles : effects of material properties As we described in the Introduction , the capacity of nano - sized objects to interact with the cellular machinery has opened up the possibility of using nano - sized materials to deliver drugs to their target . Nanoparticle design can be tailored to target specif - ic cell types or pathways . Size , charge , shape [ 107 ] , hydropho - bicity [ 108 ] , rigidity [ 109 , 110 ] , roughness [ 111 ] and surface functionalization [ 43 , 112 ] of nanomaterials are all parameters that in principle can be tuned in order to affect the pathway of internalization of nano - sized materials and ideally also to direct them towards a specific intracellular location . Still , there is not yet an agreement in the scientific community on the pathways that nano - sized materials , including nanomedicines , use to enter cells [ 21 , 22 , 113 , 114 ] . A better characterization of the mecha - nisms that cells use to internalize nano - sized materials can potentially help us to understand how to tune their design to achieve the desired outcomes at cell level [ 22 ] ( as we illustrate in Figure 1 ) . Nanoparticle size : A fundamental parameter that seems to affect the pathway of internalization of nanoparticles is their size . A general observation is that the uptake efficiency of nanomaterials decreases with increasing particle size [ 115 - 117 ] , probably because of the extensive membrane rearrangements needed for internalization of larger objects [ 59 , 118 , 119 ] . Some studies have compared explicitly the uptake efficiency of parti - cles of different sizes trying to define the optimal size for uptake [ 120 - 123 ] . Additionally , it is commonly believed that most nanoparticles with sizes compatible with the size of clathrin - coated pits enter through clathrin - mediated endo - cytosis [ 115 , 124 ] and , vice versa , that larger ones do not . It was thought that the geometry and 3D structure of clathrin would not allow it . However , results opposing this general idea about size have also been reported [ 116 , 125 - 127 ] . For example , in one study using HEK293 cells , spherical polystyrene nano - particles of 100 nm were internalized through actin - dependent but clathrin - independent processes , and vice versa , 200 nm nanoparticles entered by clathrin - mediated endocytosis [ 127 ] . Similarly , the uptake of 500 nm PRINT particles was reduced by chlorpromazine ( an inhibitor of clathrin - dependent endo - cytosis ) [ 125 ] and it has been shown that larger particles could be internalized in pits coated with plaques of clathrin [ 128 - 130 ] . These studies , selected just as examples among many others , already highlight the difficulties in establishing a general rule on how nanoparticle size affects uptake . Similarly , it was believed that particles larger than 200 nm could not be internal - ized by non - phagocytic cells [ 7 ] , while opposite observations are often reported . For instance , even cubic nanoparticles of 3 μ m could be internalized by HeLa cells [ 125 ] . Moreover , the effects of nanoparticle size on the mechanism of uptake may be different in different cell types . For example , it has been shown that murine RAW 264 . 7 macrophages have a higher uptake efficiency for carboxylated polystyrene nanopar - ticles compared to human endothelial HCMEC or epithelial HeLa cells [ 131 ] . In another study using carboxylated poly - styrene nanoparticles of different sizes in different cell types , actin was required for the internalization of nanoparticles of 200 nm , but not for those of 40 nm in 1321N1 astrocytes . Instead , in lung epithelial A549 cells , for both nanoparticle sizes , the uptake was not dependent on actin [ 132 ] . Unfortu - nately , so far , only a few studies have investigated in a system - atic way how different cell types internalize nanoparticles of different size , making it difficult to draw conclusions [ 132 - 134 ] . Nanoparticle charge : Apart from size , charge is another easily tunable parameter that can greatly influence the behaviour of nanoparticles in biological media [ 135 ] and on cells [ 136 ] . In general , positively charged nanoparticles seem to be internal - ized more efficiently than neutral and negatively charged parti - cles [ 125 , 137 , 138 ] . However , there are other examples showing exactly the opposite [ 139 ] . It has also been reported that uptake increases with charge density ( either positive or negative ) [ 140 ] . Regarding the pathway of internalization , some studies sug - gested that positively charged nanomaterials are predominantly internalized through clathrin - mediated endocytosis , with a frac - tion of particles utilizing macropinocytosis , while negatively charged nanoparticles are more likely to use a cholesterol - de - pendent mechanism for their internalization [ 21 , 141 ] . Contra - dicting results were reported in which clathrin - mediated endo - cytosis did not seem to be a relevant pathway for neither posi - tively nor negatively charged nanomaterials , while cholesterol - mediated uptake seems to be equally important for both [ 142 ] . Similarly , another study suggested that both negatively and pos - itively charged poly ( ethylene glycol ) - ᴅ , ʟ - polylactic acid parti - cles entered , at least partially , by clathrin - mediated endocytosis and macropinocytosis [ 143 ] . It is important to mention that many studies investigating the effect of charge or other nanomaterial properties on cellular interactions were performed in the absence of proteins from bi - ological fluids such as serum . This represents a further issue since the charge of nanomaterials tends towards neutrality upon corona formation , once they are applied in a biological environ - ment . Thus , nanoparticles that in water possess different charges might end up having all a similar charge , close to neut - rality upon exposure to biological media [ 135 ] . Because of this , it is important to determine whether some of the described charge - related effects disappear once the nanomaterials are applied in a biological environment . Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 344 Nanoparticle shape : Another tunable parameter that can influ - ence nanoparticle – cell interactions is shape . Simulations indi - cated that based on the energy required for membrane bending , the uptake would be the highest for spheres followed by cubes , then rods , and lastly discs [ 144 ] . Nevertheless , a recent in vitro study using gold particles , showed that the number of internal - ized particles was decreasing from rod to cubic , to spherical , to prism - shaped nanoparticles [ 145 ] . Often the effect of shape is studied by changing nanoparticle aspect ratio . Most of these studies showed that the uptake is higher when the aspect ratio is smaller [ 120 , 146 , 147 ] . This could be explained by the higher energy required to wrap a lipid membrane around a nanoparti - cle with high aspect ratio [ 148 ] . However , also in relation to this aspect , conflicting results were found in which cross - linked poly ( ethylene glycol ) hydrogels or mesoporous silica particles with higher aspect ratio were internalized quicker and more than those with low aspect ratio [ 125 , 149 ] . A few studies have investigated the effect of nanoparticle shape not only on uptake efficiency but also on the endocytic mechanisms involved in uptake [ 125 , 134 , 150 ] . Cylindric cationic poly ( ethylene glycol ) hydrogels with two different aspect ratios ( 1 and 3 ) were both taken up by HeLa cells by a combination of clathrin - mediated and caveolae - mediated endocytosis ( based on cholesterol and tyrosine kinase dependence ) [ 125 ] . On the other hand , in another study , the entry of cylindric , worm - like , and spherical silica particles in A549 and RAW264 . 7 cells was independent of cholesterol . Uptake of spherical silica particles was mainly clathrin - dependent , while internalization of worm - like and cylindric silica was primarily microtubule - dependent [ 134 ] . Similar studies on the effect of shape on the mechanism of internalization are challenging because of different complic - ating factors . Firstly , changing the shape also affects the dimen - sions of the nanomaterial . This means that to compare uptake of differently shaped objects , either the volume , maximum diame - ter , or a combination of the dimensions should be kept constant . Secondly , non - spherical objects can interact with the cell mem - brane with different orientation . Thus , depending on the orien - tation when interacting with the cell membrane , the contact area between the nano - sized object and the cell surface differs . It is thought that in these cases different mechanisms are then trig - gered based on the orientation of the nanoparticles [ 134 , 150 ] . This might , at least in part , explain why multiple pathways seem to be involved in the uptake of non - spherical nanomateri - als . Nanoparticle rigidity : Recently , there is a high interest in the effect of the rigidity of nanoparticles on the interactions at cel - lular level [ 109 , 110 ] . Simulations showed a higher energy barrier for the internalization of soft and easily deformable nanoparticles than for that of rigid particles [ 151 , 152 ] . Howev - er , nanoparticle – cell interactions cannot be described solely by the energy barrier required to bend the lipid membrane . Other biological factors are also involved , possibly explaining the contrasting results on the effect of rigidity on uptake [ 110 , 151 - 154 ] . Indeed , while some studies found higher uptake for the more rigid particles [ 151 , 153 , 155 ] , another study suggested that softer particles enter in higher numbers [ 154 ] . In this latter study , it was also shown that the more rigid nanomaterial ( Young’s modulus above 13 . 8 MPa ) was internalized by cells at least in part via clathrin - mediated endocytosis , as opposed to the softer material [ 154 ] . Similarly , in another study , lipid covered PGLA particles with different Young’s modulus values in the range of gigapascals were also partially internalized by clathrin - mediated endocytosis [ 151 ] . Understanding how nanoparticle properties affect the mechanism of uptake by cells : Overall , the examples presented show that the effect of tunable nanoparticle parame - ters such as size , charge , and shape on the mechanisms of uptake by cells is often ambiguous . To further illustrate this complexity , Table 1 summarizes the few preliminary observa - tions , which we discussed in this section , including references , which support and contrast them . We emphasize that Table 1 is far from complete and the observations included have been selected solely as an example to illustrate the complexity of often contrasting outcomes reported in literature . A reason of this ambiguity and complexity might be that multiple mechanisms are triggered at the same time , as sug - gested by several studies [ 18 , 115 , 132 , 156 - 159 ] . It could also be that , besides the generally studied classical routes such as clathrin - and caveolae - mediated endocytosis , other less well - known pathways of internalization are involved in the uptake of nanomedicines , such as those briefly described in Section 2 . 1 . Recently , computer simulations and in vitro studies of nanopar - ticle – membrane interactions have shown that the surface of nanomaterials can in itself induce several changes at the plasma membrane , by determining sol – gel transitions in the lipid bilay - er and impairing lipid lateral diffusion [ 160 , 161 ] , or by induc - ing bending of the plasma membrane [ 162 , 163 ] , as already ob - served with certain viruses [ 164 ] . These changes in membrane dynamics might as well be a trigger for the endocytosis of nano - particles via alternative mechanisms , which are not yet fully characterized . Extracting conclusions from the available literature is addition - ally complicated by the fact that most studies have used differ - ent conditions with respect to many factors such as , for instance , the presence , source , and concentration of serum , but also the nanomaterial used , the cell type , and the methods applied to characterize the pathways involved . These differ - Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 345 Table 1 : The table summarizes few selected examples that we discuss in Section 2 . 2 of observations reported in literature on the effect of nanoparti - cle properties on the mechanism of uptake by cells . References to literature with supporting as well as opposing observations are included ( also dis - cussed in Section 2 . 2 ) . We emphasize that the table is far from complete and includes only a few examples , selected solely to illustrate the complexi - ty of outcomes . In fact , we consider the observations listed still as preliminary , as also illustrated by apparently contrasting results in the opposing studies included ( in most cases performed using different conditions and systems ) . reported observation or preliminary statement supporting studies opposing studies nanoparticles uptake efficiency decreases with increasing size [ 107 - 109 ] [ 112 ] nanoparticles up to 100 nm in diameter enter through clathrin - dependent endocytosis [ 107 , 113 ] [ 114 - 116 ] non - phagocytic cells can only internalize materials up to 200 nm [ 8 ] [ 107 , 114 ] positively charged nanoparticles are internalized more efficiently than negatively charged or neutral nanoparticles [ 114 , 124 , 125 , 128 , 130 ] [ 126 , 127 , 129 ] positively charged nanoparticles enter ( at least partially ) through clathrin - dependent endocytosis [ 21 , 128 , 130 ] [ 129 ] nano - sized objects with small aspect ratios are internalized more efficiently [ 112 , 133 , 134 ] [ 114 , 136 ] more rigid nanoparticles enter more efficiently than softer nanoparticles [ 139 , 141 , 143 ] [ 142 ] ences clearly lead to different outcomes and apparently conflicting results . Only in a few cases , systematic studies using a series of nanomaterials of well - defined properties have been performed in order to try to disentangle the effect of multiple nanomaterial properties on the cellular uptake and on other bio - logical effects [ 145 , 165 ] . Unfortunately , still no clear predic - tions can be made on how certain nanoparticle properties affect uptake efficiency and the mechanisms involved , and more work along these lines will be required [ 145 , 165 ] . Recent debates in the nanomedicine field pushed the community to address the issue of reproducibility and the development of standardized procedure in nanomedicine testing and application [ 166 , 167 ] . Similar efforts may help to reach a better understanding of how nanomaterial properties affect the mechanism of uptake by cells . 3 Intracellular fate Another important aspect to consider for nanomedicine applica - tions is the final fate of nano - sized materials following internal - ization . A recent review has discussed this aspect in more detail [ 85 ] . Regardless of the route of entry , many studies report that most nano - sized materials travel via the endosomes until reaching their final localization in the cell , which in most cases has been shown to be the lysosomal compartment [ 168 , 169 ] . In the lysosomes , nano - sized objects , including nanomedicines , may be degraded and release their content , if biodegradable , or may accumulate and persist [ 122 ] . While this can be very use - ful when the target is the lysosomes , it is well known that lyso - somal accumulation constitutes an ulterior barrier for the delivery of drugs to any other intracellular target [ 85 , 86 ] . This has led to the development of strategies to induce escape from the endosomal compartment , including – among others – via the so - called “proton sponge effect” [ 170 , 171 ] . Materials capable to induce this proton sponge effect started to find their application in vivo only recently [ 172 ] . Several other strategies are being developed , including some inspired by viruses and bacteria capable to travel to other intracellular locations [ 173 - 176 ] . Several reviews fully focused on endo - lysosomal escape have summarised current efforts in this direction [ 174 - 177 ] . Another open question that is debated in the field is whether nano - sized materials , including nanomedicines , can end up in compartments other than the lysosomes . For example , in several reports it appears that nanoparticles can be transcytosed across endothelial cells [ 178 , 179 ] . However , the existence of a dedic - ated pathway , such as caveolae - mediated endocytosis , for tran - scytosis of macromolecules is still debated in the endocytosis community [ 96 , 102 - 104 ] . Understanding how cells recognize and internalize nano - sized materials can help us to address also questions regarding the intracellular fate of nano - sized materials and to define strategies to direct nanomedicines towards different intracellular loca - tions or to promote drug release in cells . 4 Challenges in studying endocytosis of nano - sized materials in vitro While studying the interactions between nanomaterials and cells is extremely challenging to perform in vivo , in vitro studies can help to unravel the mechanisms involved in their uptake . For such studies , the nanoparticle dispersion , the cell culture condi - tions , the cell line investigated , and the methods used to charac - terize the uptake mechanisms are all crucial . Unfortunately , there are often no agreements on how to perform uptake studies in a standardized way . Recently , this problem has gotten much attention in the nanomedicine field [ 166 , 167 , 180 ] . Within the nanosafety community , dedicated to the study of potential hazards of nanotechnologies , several efforts have been focused Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 346 on the establishment of standardized procedures for nanomateri - al handling and for cell interaction studies in order to ensure quality in nanosafety testing [ 181 - 183 ] . Some of the know - ledge gained there could be helpful also in developing similar standards for studies aimed at characterizing how nano - sized objects , including nanomedicines , enter cells . In the following sections , we will describe some technical challenges concern - ing in vitro studies of the endocytosis of nano - sized materials . 4 . 1 Nanoparticle dispersion in biological media : agglomeration and corona formation One of the most important aspects to consider when studying nanoparticle interactions with cells , as well as when character - izing the mechanism for their internalization , is the stability over time and the potential agglomeration of nanoparticles in biological media . In fact , agglomeration can strongly affect the corona composition , the interaction with cells , as well as the pathways of internalization [ 59 , 184 , 185 ] . Thus , it is important to characterize the nanoparticle dispersion in the biological media in which the nanomedicine will be applied , and to monitor potential agglomeration and stability over time . Additionally , studies in which nanoparticles are incubated on cells without serum or other biological fluids may lead to conclusions that are not relevant for biological applications and in vivo studies , because they do not take into account corona - related effects [ 186 - 189 ] . Given the impact of the corona on both recognition and internalization of nano - sized materials , it is important not only to include some biological fluid to allow corona formation , but also to define the appropriate conditions for each application [ 18 , 62 - 65 , 68 , 69 ] . For instance , there are many in vitro studies in which nanoparticles are tested on human cell lines using culture media containing a low percent - age of foetal bovine serum [ 132 , 133 , 190 - 193 ] . Not only the percentage of serum , but also the species from which the serum originates , as well the use of serum heat inactivation , or the choice of anticoagulant used to prepare plasma are some of the factors affecting corona formation and potentially also the subsequent mechanisms of internalization [ 18 , 62 - 65 , 68 , 69 ] . Similar considerations should be made when characterizing the uptake of nanomedicines administered via other routes . In these cases biological fluids other than serum should be used [ 185 , 194 ] . On a more complex level , it is also known that the corona com - position evolves over time [ 195 - 197 ] . Recent studies from Chan and colleagues are trying to explore how the corona composi - tion affects the biological interactions of nanoparticles by per - forming mass spectrometry screenings and by developing computational models to predict the evolution of their protein corona [ 60 , 61 , 198 ] . Other studies are trying to understand not only whether certain biomolecules are present on the nanoparti - cle surface , but also their orientation , which might influence their recognition by cell receptors [ 17 , 199 ] . In order to take into account corona - related effects on nanoparticle interactions with cells , a precise workflow to characterize the corona composi - tion has been proposed , which might help to compare different studies and to find a correlation between corona composition , serum composition and , ultimately , uptake mechanisms [ 41 ] . 4 . 2 Cell models The cell type investigated and its tissue organization are other important factors that can affect the uptake mechanisms of nanoparticles . For example , not all pathways are active in all cell types : HepG2 cells have no endogenous caveolin - 1 , and therefore they are unable to internalize nanoparticles by cave - olae - mediated endocytosis [ 200 ] . Similarly , many in vitro studies use immortalized or cancer cell lines , such as HEK293 or HeLa cells , which are easy to transfect and culture . However , these cells can behave quite differently in comparison to prima - ry cells or cells isolated directly from tissues of patients . While , on one hand , the use of primary cells can be recommended , on the other hand , it is also a well - known obstacle for a detailed study of cellular pathways . Most primary cells are difficult to transfect and require interaction with other cell types for their proper differentiation [ 201 - 203 ] . Another important factor known to affect uptake pathways by cells in vitro is the differ - entiation of cells into barriers and the resulting cell polarization [ 159 ] . Uptake by cells grown to a polarized cell barrier is , in fact , different than uptake by the same cells when grown isolat - ed or simply confluent [ 22 , 159 ] . Apart from simpler cell cultures and cell barriers , many advances have been made in the development of cellular models that can better reflect the more complex organization of cells in vivo . Models such as organoids or spheroids , which use one or multiple cell lines organized into 3D structures , have been de - veloped and are likely to become useful also for nanomedicine uptake studies . 4 . 3 Methods to characterize uptake mechanisms Further difficulties in the study of the uptake mechanisms of nano - sized materials , such as nanomedicines , arise from the fact that endocytosis represents a complex cellular process with many molecules , feedback loops , and signalling cascades involved . The endocytosis field is still very active and constant - ly progressing [ 71 , 77 , 204 ] . Many processes and molecular details of these pathways are still unknown . For instance , in recent years much attention has been paid to non - canonical pathways of endocytosis [ 71 , 91 , 92 ] , which are often more diffi - cult to study , but which might as well constitute possible routes for the internalization of nano - sized materials . In light of this Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 347 complexity , the tendency within the nanomedicine field to clas - sify the pathways of internalization of drug carriers as merely macropinocytosis , clathrin - dependent , or caveolae - dependent is for sure an oversimplification . Furthermore , the classification and description of the different mechanisms of uptake by cells are often revised and corrected in the endocytosis field , as research progresses . This is an example of the challenges that interdisciplinary fields such as nanomedicine need to face . In this context , a closer connection with the cell biology and endo - cytosis communities is desirable [ 113 ] . Typical experiments to characterize uptake mechanisms are carried out by altering cellular pathways using different methods in order to determine their involvement in nanoparti - cle uptake . However , it is well established that perturbation of a cellular mechanism might as well lead to the alteration of other mechanisms . Therefore , when performing such studies , it is im - portant to have appropriate controls to verify the effect of the selected treatment on the pathway of interest and exclude poten - tial artefacts of this kind [ 22 , 133 , 158 ] . The selection of appropriate controls poses further challenges . For example , fluorescently labelled low - density lipoprotein and transferrin can be used as markers for clathrin - mediated endo - cytosis [ 205 , 206 ] , dextran as a fluid phase marker for phagocyt - osis and for the CLEE / GEEC pathway [ 193 ] , and LacCer ( C5 - lactosylceramide ) for cholesterol - dependent uptake [ 133 , 207 ] . However , while cholera toxin and SV40 were previously used as markers of caveolae - mediated endocytosis [ 95 ] , they have been found to enter cells using preferentially other routes and thus should not be used anymore as markers for this pathway [ 208 - 210 ] . Furthermore , selecting an appropriate control marker can be challenging for several of the more recently described clathrin - and caveolae - independent pathways . Next to the difficulties related to the choice of control markers , the fact that the endocytic pathways are strongly interconnected and that some components take part in multiple mechanisms also complicates further the interpretation of results . As an ex - ample of this , cytochalasin D , an inhibitor of actin polymeriza - tion [ 211 ] , has often been used to test the involvement of macropinocytosis and phagocytosis in the uptake of nanomate - rials . However , actin has been shown to be important also for other mechanisms , including clathrin - mediated endocytosis and caveolae - mediated endocytosis . Hence , perturbing the activity of actin affects multiple pathways at the same time [ 212 ] . Several techniques can be used for studying the endocytic mechanisms of nano - sized materials , each one with its advant - ages and drawbacks [ 22 , 133 ] . Among those , RNA interference ( RNAi ) is often used to shut down the expression of a single protein or even a single isoform . However , the complete deple - tion of the protein of interest after RNAi requires at least 48 – 96 h and during this time cells can adapt , for example by upregulating other proteins of the same family or other pathways . Moreover , RNAi does not guarantee the total deple - tion of a protein from the cell , and in some cases the partial reduction of a protein is not sufficient to fully inhibit its func - tion [ 22 ] . Apart from RNAi , so far , many studies on the uptake of nano - sized materials make use of transport inhibitors , whose action on cells is instead very fast . However , some of these inhibitors lack specificity , they might interfere with multiple pathways , and they can cause cellular toxicity [ 22 , 133 , 158 , 213 ] . In contrast to these approaches to block uptake pathways , other strategies can be found in which proteins are instead overex - pressed , in order to eventually detect an increase in nanoparti - cle uptake [ 17 ] . Nevertheless , also these methods might lead to artefacts , since the overexpression might induce the activation of a pathway that may not be active under physiological condi - tions [ 22 , 214 ] . Furthermore , some proteins act as heterodimers or in concert with other molecular partners , thus their overex - pression might not produce any detectable effect if not combined with the overexpression of those partners as well . Overexpression is often used to allow for the visualization of fluorescently tagged molecules by microscopy . However , also this might lead to additional artefacts . For example , it has been shown that overexpression of GFP - tagged caveolin 1 ( CAV1 - GFP ) , the main constituent of caveolae - mediated endocytosis , leads to the creation of artefacts , such as the observation of a specialized endosomal compartment for caveolae , the “caveo - some” [ 214 ] . Recent advances in cellular imaging and gene editing could overcome some of these issues . For instance , the use of stably transfected cell lines might be a good solution when the total depletion of a protein is required to shut down a pathway ( often difficult to achieve with techniques such as RNAi ) , but also for expressing labelled proteins at physiological levels , thereby avoiding the aforementioned artefacts connected to overexpres - sion . The creation of specific transgenic cell lines to study nanoparticle uptake has been greatly enhanced by gene editing techniques such as CRISPR / CAS9 , which allows to cut genes in a much more specific and efficient way than with previously existing methods [ 215 , 216 ] . Similar methodologies can improve our understanding of the involvement of specific pro - teins in the internalization of nanoparticles . Other recently developed techniques that are available in cell biology to characterize pathways and that have not yet been used to study the uptake of nano - sized materials Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 348 may provide novel insights into this difficult question . For instance , so - called OMICS approaches based on large - scale proteomics and full genome screenings could be of particular use [ 217 - 219 ] . While most of the “classical” methods mentioned so far require previous knowledge on the mecha - nisms of uptake by cells , a reverse approach could allow for discovering novel targets not yet associated with the endo - cytosis of nanomaterials . Overall , it is clear that none of these different methods , alone , can provide a full picture of the mechanisms that nano - sized materials use to interact with cells since they all display differ - ent advantages and pitfalls [ 22 , 133 , 158 ] . The combination of different techniques and the application of proper controls could help us to gain a better knowledge of the endocytic processes involved in the uptake of nano - sized materials . Conclusion Nanomedicine aims at delivering drugs more efficiently to their target to treat diseases . Designing the properties of nano - sized materials to be able to control the interactions and the behav - iour at cell level is one of the key steps required for successful targeting . Nanomedicines can be functionalized by the addition of targeting moieties to be recognized by specific receptors on the targeted cells . However , achieving this initial recognition for active targeting still holds many challenges . Additionally , it has emerged that when nano - sized materials are applied in a biological environment , corona formation affects the initial recognition by cells , as well as the following mecha - nisms of internalization . However , many aspects of the initial recognition of nano - sized materials by cell receptors still need to be understood . Similarly , how the initial recognition affects the following mechanisms of internalization remains to be elu - cidated and an agreement in the scientific community about the pathways that nano - sized materials , such as nanomedicines , use to enter cells is still missing . Several factors complicate these studies and make it difficult to draw clear conclusions . The field of endocytosis is still very active and novel pathways are still being described . At the same time there are limits and challenges regarding the many differ - ent methods available to characterize uptake mechanisms and the lack of standardized procedures makes it difficult to draw conclusions from available studies . Using a combination of methods and appropriate controls to study the mechanisms by which cells internalize nano - sized materials could potentially help us to understand how these are affected by nanomaterial properties . In this way , nanomedicine design could be tuned to achieve the desired outcomes at cell level and engineer nanoma - terials for more efficient drug targeting . Funding This work was funded by the European Research Council ( ERC ) under the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement no . 637614 ( NanoPaths ) . A . S . kindly acknowledges the University of Groningen for additional funding ( Rosalind Franklin Fellow - ship ) . ORCID ® iDs Valentina Francia - https : / / orcid . org / 0000 - 0003 - 4911 - 6832 Daphne Montizaan - https : / / orcid . org / 0000 - 0001 - 8514 - 0317 Anna Salvati - https : / / orcid . org / 0000 - 0002 - 9339 - 0161 References 1 . Wolfram , J . ; Ferrari , M . Nano Today 2019 , 25 , 85 – 98 . doi : 10 . 1016 / j . nantod . 2019 . 02 . 005 2 . Peer , D . ; Karp , J . M . ; Hong , S . ; Farokhzad , O . C . ; Margalit , R . ; Langer , R . Nat . Nanotechnol . 2007 , 2 , 751 – 760 . doi : 10 . 1038 / nnano . 2007 . 387 3 . Shi , J . ; Kantoff , P . W . ; Wooster , R . ; Farokhzad , O . C . Nat . Rev . Cancer 2017 , 17 , 20 – 37 . doi : 10 . 1038 / nrc . 2016 . 108 4 . Sandvig , K . ; van Deurs , B . Gene Ther . 2005 , 12 , 865 – 872 . doi : 10 . 1038 / sj . gt . 3302525 5 . Bareford , L . M . ; Swaan , P . W . Adv . Drug Delivery Rev . 2007 , 59 , 748 – 758 . doi : 10 . 1016 / j . addr . 2007 . 06 . 008 6 . Bobo , D . ; Robinson , K . J . ; Islam , J . ; Thurecht , K . J . ; Corrie , S . R . Pharm . Res . 2016 , 33 , 2373 – 2387 . doi : 10 . 1007 / s11095 - 016 - 1958 - 5 7 . Petros , R . A . ; DeSimone , J . M . Nat . Rev . Drug Discovery 2010 , 9 , 615 – 627 . doi : 10 . 1038 / nrd2591 8 . Duan , X . ; Li , Y . Small 2013 , 9 , 1521 – 1532 . doi : 10 . 1002 / smll . 201201390 9 . Chauhan , V . P . ; Jain , R . K . Nat . Mater . 2013 , 12 , 958 – 962 . doi : 10 . 1038 / nmat3792 10 . Allen , T . M . Nat . Rev . Cancer 2002 , 2 , 750 – 763 . doi : 10 . 1038 / nrc903 11 . Villaverde , G . ; Baeza , A . Beilstein J . Nanotechnol . 2019 , 10 , 168 – 181 . doi : 10 . 3762 / bjnano . 10 . 16 12 . Bertrand , N . ; Wu , J . ; Xu , X . ; Kamaly , N . ; Farokhzad , O . C . Adv . Drug Delivery Rev . 2014 , 66 , 2 – 25 . doi : 10 . 1016 / j . addr . 2013 . 11 . 009 13 . Danhier , F . ; Feron , O . ; Préat , V . J . Controlled Release 2010 , 148 , 135 – 146 . doi : 10 . 1016 / j . jconrel . 2010 . 08 . 027 14 . Sykes , E . A . ; Chen , J . ; Zheng , G . ; Chan , W . C . W . ACS Nano 2014 , 8 , 5696 – 5706 . doi : 10 . 1021 / nn500299p 15 . Salvati , A . ; Pitek , A . S . ; Monopoli , M . P . ; Prapainop , K . ; Bombelli , F . B . ; Hristov , D . R . ; Kelly , P . M . ; Åberg , C . ; Mahon , E . ; Dawson , K . A . Nat . Nanotechnol . 2013 , 8 , 137 – 143 . doi : 10 . 1038 / nnano . 2012 . 237 16 . Hadjidemetriou , M . ; Al - Ahmady , Z . ; Mazza , M . ; Collins , R . F . ; Dawson , K . ; Kostarelos , K . ACS Nano 2015 , 9 , 8142 – 8156 . doi : 10 . 1021 / acsnano . 5b03300 17 . Lara , S . ; Alnasser , F . ; Polo , E . ; Garry , D . ; Lo Giudice , M . C . ; Hristov , D . R . ; Rocks , L . ; Salvati , A . ; Yan , Y . ; Dawson , K . A . ACS Nano 2017 , 11 , 1884 – 1893 . doi : 10 . 1021 / acsnano . 6b07933 18 . Francia , V . ; Yang , K . ; Deville , S . ; Reker - Smit , C . ; Nelissen , I . ; Salvati , A . ACS Nano 2019 , 13 , 11107 – 11121 . doi : 10 . 1021 / acsnano . 9b03824 Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 349 19 . Duncan , R . ; Richardson , S . C . W . Mol . Pharmaceutics 2012 , 9 , 2380 – 2402 . doi : 10 . 1021 / mp300293n 20 . Oh , N . ; Park , J . H . Int . J . Nanomed . 2014 , 9 ( Suppl . 1 ) , 51 – 63 . doi : 10 . 2147 / ijn . s26592 21 . Sahay , G . ; Alakhova , D . Y . ; Kabanov , A . V . J . Controlled Release 2010 , 145 , 182 – 195 . doi : 10 . 1016 / j . jconrel . 2010 . 01 . 036 22 . Iversen , T . - G . ; Skotland , T . ; Sandvig , K . Nano Today 2011 , 6 , 176 – 185 . doi : 10 . 1016 / j . nantod . 2011 . 02 . 003 23 . Sudimack , J . ; Lee , R . J . Adv . Drug Delivery Rev . 2000 , 41 , 147 – 162 . doi : 10 . 1016 / s0169 - 409x ( 99 ) 00062 - 9 24 . Daniels , T . R . ; Bernabeu , E . ; Rodríguez , J . A . ; Patel , S . ; Kozman , M . ; Chiappetta , D . A . ; Holler , E . ; Ljubimova , J . Y . ; Helguera , G . ; Penichet , M . L . Biochim . Biophys . Acta , Gen . Subj . 2012 , 1820 , 291 – 317 . doi : 10 . 1016 / j . bbagen . 2011 . 07 . 016 25 . Mattheolabakis , G . ; Milane , L . ; Singh , A . ; Amiji , M . M . J . Drug Targeting 2015 , 23 , 605 – 618 . doi : 10 . 3109 / 1061186x . 2015 . 1052072 26 . Wilhelm , S . ; Tavares , A . J . ; Dai , Q . ; Ohta , S . ; Audet , J . ; Dvorak , H . F . ; Chan , W . C . W . Nat . Rev . Mater . 2016 , 1 , 16014 . doi : 10 . 1038 / natrevmats . 2016 . 14 27 . McNeil , S . E . Nat . Rev . Mater . 2016 , 1 , 16073 . doi : 10 . 1038 / natrevmats . 2016 . 73 28 . Lammers , T . ; Kiessling , F . ; Ashford , M . ; Hennink , W . ; Crommelin , D . ; Storm , G . Nat . Rev . Mater . 2016 , 1 , 16069 . doi : 10 . 1038 / natrevmats . 2016 . 69 29 . Danhier , F . J . Controlled Release 2016 , 244 , 108 – 121 . doi : 10 . 1016 / j . jconrel . 2016 . 11 . 015 30 . Olivier , V . ; Meisen , I . ; Meckelein , B . ; Hirst , T . R . ; Peter - Katalinic , J . ; Schmidt , M . A . ; Frey , A . Bioconjugate Chem . 2003 , 14 , 1203 – 1208 . doi : 10 . 1021 / bc034077z 31 . Aubin - Tam , M . - E . ; Hwang , W . ; Hamad - Schifferli , K . Proc . Natl . Acad . Sci . U . S . A . 2009 , 106 , 4095 – 4100 . doi : 10 . 1073 / pnas . 0807299106 32 . Kogot , J . M . ; Parker , A . M . ; Lee , J . ; Blaber , M . ; Strouse , G . F . ; Logan , T . M . Bioconjugate Chem . 2009 , 20 , 2106 – 2113 . doi : 10 . 1021 / bc900224d 33 . Muro , S . J . Controlled Release 2012 , 164 , 125 – 137 . doi : 10 . 1016 / j . jconrel . 2012 . 05 . 052 34 . Mahon , E . ; Salvati , A . ; Baldelli Bombelli , F . ; Lynch , I . ; Dawson , K . A . J . Controlled Release 2012 , 161 , 164 – 174 . doi : 10 . 1016 / j . jconrel . 2012 . 04 . 009 35 . Ruoslahti , E . ; Bhatia , S . N . ; Sailor , M . J . J . Cell Biol . 2010 , 188 , 759 – 768 . doi : 10 . 1083 / jcb . 200910104 36 . Monopoli , M . P . ; Åberg , C . ; Salvati , A . ; Dawson , K . A . Nat . Nanotechnol . 2012 , 7 , 779 – 786 . doi : 10 . 1038 / nnano . 2012 . 207 37 . Mahmoudi , M . ; Lynch , I . ; Ejtehadi , M . R . ; Monopoli , M . P . ; Bombelli , F . B . ; Laurent , S . Chem . Rev . 2011 , 111 , 5610 – 5637 . doi : 10 . 1021 / cr100440g 38 . Cedervall , T . ; Lynch , I . ; Lindman , S . ; Berggard , T . ; Thulin , E . ; Nilsson , H . ; Dawson , K . A . ; Linse , S . Proc . Natl . Acad . Sci . U . S . A . 2007 , 104 , 2050 – 2055 . doi : 10 . 1073 / pnas . 0608582104 39 . Schöttler , S . ; Landfester , K . ; Mailänder , V . Angew . Chem . , Int . Ed . 2016 , 55 , 8806 – 8815 . doi : 10 . 1002 / anie . 201602233 40 . Tonigold , M . ; Simon , J . ; Estupiñán , D . ; Kokkinopoulou , M . ; Reinholz , J . ; Kintzel , U . ; Kaltbeitzel , A . ; Renz , P . ; Domogalla , M . P . ; Steinbrink , K . ; Lieberwirth , I . ; Crespy , D . ; Landfester , K . ; Mailänder , V . Nat . Nanotechnol . 2018 , 13 , 862 – 869 . doi : 10 . 1038 / s41565 - 018 - 0171 - 6 41 . Chetwynd , A . J . ; Wheeler , K . E . ; Lynch , I . Nano Today 2019 , 28 , 100758 . doi : 10 . 1016 / j . nantod . 2019 . 06 . 004 42 . Harris , J . M . ; Martin , N . E . ; Modi , M . Clin . Pharmacokinet . 2001 , 40 , 539 – 551 . doi : 10 . 2165 / 00003088 - 200140070 - 00005 43 . Howard , M . D . ; Jay , M . ; Dziubla , T . D . ; Lu , X . J . Biomed . Nanotechnol . 2008 , 4 , 133 – 148 . doi : 10 . 1166 / jbn . 2008 . 021 44 . García , K . P . ; Zarschler , K . ; Barbaro , L . ; Barreto , J . A . ; O ' Malley , W . ; Spiccia , L . ; Stephan , H . ; Graham , B . Small 2014 , 10 , 2516 – 2529 . doi : 10 . 1002 / smll . 201303540 45 . Safavi - Sohi , R . ; Maghari , S . ; Raoufi , M . ; Jalali , S . A . ; Hajipour , M . J . ; Ghassempour , A . ; Mahmoudi , M . ACS Appl . Mater . Interfaces 2016 , 8 , 22808 – 22818 . doi : 10 . 1021 / acsami . 6b05099 46 . Schöttler , S . ; Becker , G . ; Winzen , S . ; Steinbach , T . ; Mohr , K . ; Landfester , K . ; Mailänder , V . ; Wurm , F . R . Nat . Nanotechnol . 2016 , 11 , 372 – 377 . doi : 10 . 1038 / nnano . 2015 . 330 47 . Dai , Q . ; Walkey , C . ; Chan , W . C . W . Angew . Chem . , Int . Ed . 2014 , 53 , 5093 – 5096 . doi : 10 . 1002 / anie . 201309464 48 . Lundqvist , M . ; Stigler , J . ; Elia , G . ; Lynch , I . ; Cedervall , T . ; Dawson , K . A . Proc . Natl . Acad . Sci . U . S . A . 2008 , 105 , 14265 – 14270 . doi : 10 . 1073 / pnas . 0805135105 49 . Caracciolo , G . ; Cardarelli , F . ; Pozzi , D . ; Salomone , F . ; Maccari , G . ; Bardi , G . ; Capriotti , A . L . ; Cavaliere , C . ; Papi , M . ; Laganà , A . ACS Appl . Mater . Interfaces 2013 , 5 , 13171 – 13179 . doi : 10 . 1021 / am404171h 50 . Deng , Z . J . ; Liang , M . ; Monteiro , M . ; Toth , I . ; Minchin , R . F . Nat . Nanotechnol . 2011 , 6 , 39 – 44 . doi : 10 . 1038 / nnano . 2010 . 250 51 . Gilleron , J . ; Querbes , W . ; Zeigerer , A . ; Borodovsky , A . ; Marsico , G . ; Schubert , U . ; Manygoats , K . ; Seifert , S . ; Andree , C . ; Stöter , M . ; Epstein - Barash , H . ; Zhang , L . ; Koteliansky , V . ; Fitzgerald , K . ; Fava , E . ; Bickle , M . ; Kalaidzidis , Y . ; Akinc , A . ; Maier , M . ; Zerial , M . Nat . Biotechnol . 2013 , 31 , 638 – 646 . doi : 10 . 1038 / nbt . 2612 52 . Akinc , A . ; Querbes , W . ; De , S . ; Qin , J . ; Frank - Kamenetsky , M . ; Jayaprakash , K . N . ; Jayaraman , M . ; Rajeev , K . G . ; Cantley , W . L . ; Dorkin , J . R . ; Butler , J . S . ; Qin , L . ; Racie , T . ; Sprague , A . ; Fava , E . ; Zeigerer , A . ; Hope , M . J . ; Zerial , M . ; Sah , D . W . Y . ; Fitzgerald , K . ; Tracy , M . A . ; Manoharan , M . ; Koteliansky , V . ; de Fougerolles , A . ; Maier , M . A . Mol . Ther . 2010 , 18 , 1357 – 1364 . doi : 10 . 1038 / mt . 2010 . 85 53 . Akinc , A . ; Maier , M . A . ; Manoharan , M . ; Fitzgerald , K . ; Jayaraman , M . ; Barros , S . ; Ansell , S . ; Du , X . ; Hope , M . J . ; Madden , T . D . ; Mui , B . L . ; Semple , S . C . ; Tam , Y . K . ; Ciufolini , M . ; Witzigmann , D . ; Kulkarni , J . A . ; van der Meel , R . ; Cullis , P . R . Nat . Nanotechnol . 2019 , 14 , 1084 – 1087 . doi : 10 . 1038 / s41565 - 019 - 0591 - y 54 . Tenzer , S . ; Docter , D . ; Rosfa , S . ; Wlodarski , A . ; Kuharev , J . ; Rekik , A . ; Knauer , S . K . ; Bantz , C . ; Nawroth , T . ; Bier , C . ; Sirirattanapan , J . ; Mann , W . ; Treuel , L . ; Zellner , R . ; Maskos , M . ; Schild , H . ; Stauber , R . H . ACS Nano 2011 , 5 , 7155 – 7167 . doi : 10 . 1021 / nn201950e 55 . Fleischer , C . C . ; Payne , C . K . J . Phys . Chem . B 2014 , 118 , 14017 – 14026 . doi : 10 . 1021 / jp502624n 56 . Zhang , Z . ; Wang , C . ; Zha , Y . ; Hu , W . ; Gao , Z . ; Zang , Y . ; Chen , J . ; Zhang , J . ; Dong , L . ACS Nano 2015 , 9 , 2405 – 2419 . doi : 10 . 1021 / nn505166x 57 . Prapainop , K . ; Witter , D . P . ; Wentworth , P . , Jr . J . Am . Chem . Soc . 2012 , 134 , 4100 – 4103 . doi : 10 . 1021 / ja300537u 58 . Gaspar , R . Nat . Nanotechnol . 2013 , 8 , 79 – 80 . doi : 10 . 1038 / nnano . 2013 . 11 59 . Nel , A . E . ; Mädler , L . ; Velegol , D . ; Xia , T . ; Hoek , E . M . V . ; Somasundaran , P . ; Klaessig , F . ; Castranova , V . ; Thompson , M . Nat . Mater . 2009 , 8 , 543 – 557 . doi : 10 . 1038 / nmat2442 60 . Lazarovits , J . ; Sindhwani , S . ; Tavares , A . J . ; Zhang , Y . ; Song , F . ; Audet , J . ; Krieger , J . R . ; Syed , A . M . ; Stordy , B . ; Chan , W . C . W . ACS Nano 2019 , 13 , 8023 – 8034 . doi : 10 . 1021 / acsnano . 9b02774 Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 350 61 . Walkey , C . D . ; Olsen , J . B . ; Song , F . ; Liu , R . ; Guo , H . ; Olsen , D . W . H . ; Cohen , Y . ; Emili , A . ; Chan , W . C . W . ACS Nano 2014 , 8 , 2439 – 2455 . doi : 10 . 1021 / nn406018q 62 . Pisani , C . ; Rascol , E . ; Dorandeu , C . ; Gaillard , J . - C . ; Charnay , C . ; Guari , Y . ; Chopineau , J . ; Armengaud , J . ; Devoisselle , J . - M . ; Prat , O . PLoS One 2017 , 12 , e0182906 . doi : 10 . 1371 / journal . pone . 0182906 63 . Schöttler , S . ; Klein , K . ; Landfester , K . ; Mailänder , V . Nanoscale 2016 , 8 , 5526 – 5536 . doi : 10 . 1039 / c5nr08196c 64 . Mirshafiee , V . ; Kim , R . ; Mahmoudi , M . ; Kraft , M . L . Int . J . Biochem . Cell Biol . 2016 , 75 , 188 – 195 . doi : 10 . 1016 / j . biocel . 2015 . 11 . 019 65 . Lesniak , A . ; Campbell , A . ; Monopoli , M . P . ; Lynch , I . ; Salvati , A . ; Dawson , K . A . Biomaterials 2010 , 31 , 9511 – 9518 . doi : 10 . 1016 / j . biomaterials . 2010 . 09 . 049 66 . Monopoli , M . P . ; Walczyk , D . ; Campbell , A . ; Elia , G . ; Lynch , I . ; Baldelli Bombelli , F . ; Dawson , K . A . J . Am . Chem . Soc . 2011 , 133 , 2525 – 2534 . doi : 10 . 1021 / ja107583h 67 . Partikel , K . ; Korte , R . ; Mulac , D . ; Humpf , H . - U . ; Langer , K . Beilstein J . Nanotechnol . 2019 , 10 , 1002 – 1015 . doi : 10 . 3762 / bjnano . 10 . 101 68 . Hajipour , M . J . ; Laurent , S . ; Aghaie , A . ; Rezaee , F . ; Mahmoudi , M . Biomater . Sci . 2014 , 2 , 1210 . doi : 10 . 1039 / c4bm00131a 69 . Corbo , C . ; Molinaro , R . ; Tabatabaei , M . ; Farokhzad , O . C . ; Mahmoudi , M . Biomater . Sci . 2017 , 5 , 378 – 387 . doi : 10 . 1039 / c6bm00921b 70 . Doherty , G . J . ; McMahon , H . T . Annu . Rev . Biochem . 2009 , 78 , 857 – 902 . doi : 10 . 1146 / annurev . biochem . 78 . 081307 . 110540 71 . Ferreira , A . P . A . ; Boucrot , E . Trends Cell Biol . 2018 , 28 , 188 – 200 . doi : 10 . 1016 / j . tcb . 2017 . 11 . 004 72 . Johannes , L . ; Mayor , S . Cell 2010 , 142 , 507 – 510 . doi : 10 . 1016 / j . cell . 2010 . 08 . 007 73 . Johannes , L . ; Parton , R . G . ; Bassereau , P . ; Mayor , S . Nat . Rev . Mol . Cell Biol . 2015 , 16 , 311 – 321 . doi : 10 . 1038 / nrm3968 74 . Graham , T . R . ; Kozlov , M . M . Curr . Opin . Cell Biol . 2010 , 22 , 430 – 436 . doi : 10 . 1016 / j . ceb . 2010 . 05 . 002 75 . Posor , Y . ; Eichhorn - Grünig , M . ; Haucke , V . Biochim . Biophys . Acta , Mol . Cell Biol . Lipids 2015 , 1851 , 794 – 804 . doi : 10 . 1016 / j . bbalip . 2014 . 09 . 014 76 . Johannes , L . ; Wunder , C . ; Shafaq - Zadah , M . J . Mol . Biol . 2016 , 428 , 4792 – 4818 . doi : 10 . 1016 / j . jmb . 2016 . 10 . 027 77 . McMahon , H . T . ; Boucrot , E . J . Cell Sci . 2015 , 128 , 1065 – 1070 . doi : 10 . 1242 / jcs . 114454 78 . McMahon , H . T . ; Gallop , J . L . Nature 2005 , 438 , 590 – 596 . doi : 10 . 1038 / nature04396 79 . Boucrot , E . ; Pick , A . ; Çamdere , G . ; Liska , N . ; Evergren , E . ; McMahon , H . T . ; Kozlov , M . M . Cell 2012 , 149 , 124 – 136 . doi : 10 . 1016 / j . cell . 2012 . 01 . 047 80 . Simunovic , M . ; Manneville , J . - B . ; Renard , H . - F . ; Evergren , E . ; Raghunathan , K . ; Bhatia , D . ; Kenworthy , A . K . ; Voth , G . A . ; Prost , J . ; McMahon , H . T . ; Johannes , L . ; Bassereau , P . ; Callan - Jones , A . Cell 2017 , 170 , 172 – 184 . e11 . doi : 10 . 1016 / j . cell . 2017 . 05 . 047 81 . Römer , W . ; Pontani , L . - L . ; Sorre , B . ; Rentero , C . ; Berland , L . ; Chambon , V . ; Lamaze , C . ; Bassereau , P . ; Sykes , C . ; Gaus , K . ; Johannes , L . Cell 2010 , 140 , 540 – 553 . doi : 10 . 1016 / j . cell . 2010 . 01 . 010 82 . Bashkirov , P . V . ; Akimov , S . A . ; Evseev , A . I . ; Schmid , S . L . ; Zimmerberg , J . ; Frolov , V . A . Cell 2008 , 135 , 1276 – 1286 . doi : 10 . 1016 / j . cell . 2008 . 11 . 028 83 . Pucadyil , T . J . ; Schmid , S . L . Cell 2008 , 135 , 1263 – 1275 . doi : 10 . 1016 / j . cell . 2008 . 11 . 020 84 . Johannes , L . ; Wunder , C . ; Bassereau , P . Cold Spring Harbor Perspect . Biol . 2014 , 6 , a016741 . doi : 10 . 1101 / cshperspect . a016741 85 . Patel , S . ; Kim , J . ; Herrera , M . ; Mukherjee , A . ; Kabanov , A . V . ; Sahay , G . Adv . Drug Delivery Rev . 2019 , 144 , 90 – 111 . doi : 10 . 1016 / j . addr . 2019 . 08 . 004 86 . Canton , I . ; Battaglia , G . Chem . Soc . Rev . 2012 , 41 , 2718 – 2739 . doi : 10 . 1039 / c2cs15309b 87 . Fujimoto , L . M . ; Roth , R . ; Heuser , J . E . ; Schmid , S . L . Traffic 2000 , 1 , 161 – 171 . doi : 10 . 1034 / j . 1600 - 0854 . 2000 . 010208 . x 88 . Kaksonen , M . ; Toret , C . P . ; Drubin , D . G . Nat . Rev . Mol . Cell Biol . 2006 , 7 , 404 – 414 . doi : 10 . 1038 / nrm1940 89 . Merrifield , C . J . ; Perrais , D . ; Zenisek , D . Cell 2005 , 121 , 593 – 606 . doi : 10 . 1016 / j . cell . 2005 . 03 . 015 90 . Cureton , D . K . ; Massol , R . H . ; Whelan , S . P . J . ; Kirchhausen , T . PLoS Pathog . 2010 , 6 , e1001127 . doi : 10 . 1371 / journal . ppat . 1001127 91 . Hansen , C . G . ; Nichols , B . J . J . Cell Sci . 2009 , 122 , 1713 – 1721 . doi : 10 . 1242 / jcs . 033951 92 . Sandvig , K . ; Pust , S . ; Skotland , T . ; van Deurs , B . Curr . Opin . Cell Biol . 2011 , 23 , 413 – 420 . doi : 10 . 1016 / j . ceb . 2011 . 03 . 007 93 . Gao , Y . - s . ; Hubbert , C . C . ; Lu , J . ; Lee , Y . - S . ; Lee , J . - Y . ; Yao , T . - P . Mol . Cell . Biol . 2007 , 27 , 8637 – 8647 . doi : 10 . 1128 / mcb . 00393 - 07 94 . Grimmer , S . ; van Deurs , B . ; Sandvig , K . J . Cell Sci . 2002 , 115 , 2953 – 2962 . 95 . Pelkmans , L . ; Helenius , A . Traffic 2002 , 3 , 311 – 320 . doi : 10 . 1034 / j . 1600 - 0854 . 2002 . 30501 . x 96 . Kirkham , M . ; Parton , R . G . Biochim . Biophys . Acta , Mol . Cell Res . 2005 , 1745 , 273 – 286 . doi : 10 . 1016 / j . bbamcr . 2005 . 06 . 002 97 . Chaudhary , N . ; Gomez , G . A . ; Howes , M . T . ; Lo , H . P . ; McMahon , K . - A . ; Rae , J . A . ; Schieber , N . L . ; Hill , M . M . ; Gaus , K . ; Yap , A . S . ; Parton , R . G . PLoS Biol . 2014 , 12 , e1001832 . doi : 10 . 1371 / journal . pbio . 1001832 98 . Stoeber , M . ; Stoeck , I . K . ; Hänni , C . ; Bleck , C . K . E . ; Balistreri , G . ; Helenius , A . EMBO J . 2012 , 31 , 2350 – 2364 . doi : 10 . 1038 / emboj . 2012 . 98 99 . Boucrot , E . ; Howes , M . T . ; Kirchhausen , T . ; Parton , R . G . J . Cell Sci . 2011 , 124 , 1965 – 1972 . doi : 10 . 1242 / jcs . 076570 100 . Oh , P . ; Borgström , P . ; Witkiewicz , H . ; Li , Y . ; Borgström , B . J . ; Chrastina , A . ; Iwata , K . ; Zinn , K . R . ; Baldwin , R . ; Testa , J . E . ; Schnitzer , J . E . Nat . Biotechnol . 2007 , 25 , 327 – 337 . doi : 10 . 1038 / nbt1292 101 . van Deurs , B . ; Roepstorff , K . ; Hommelgaard , A . M . ; Sandvig , K . Trends Cell Biol . 2003 , 13 , 92 – 100 . doi : 10 . 1016 / s0962 - 8924 ( 02 ) 00039 - 9 102 . Shvets , E . ; Bitsikas , V . ; Howard , G . ; Hansen , C . G . ; Nichols , B . J . Nat . Commun . 2015 , 6 , 6867 . doi : 10 . 1038 / ncomms7867 103 . Thomsen , P . ; Roepstorff , K . ; Stahlhut , M . ; van Deurs , B . Mol . Biol . Cell 2002 , 13 , 238 – 250 . doi : 10 . 1091 / mbc . 01 - 06 - 0317 104 . Pelkmans , L . ; Zerial , M . Nature 2005 , 436 , 128 – 133 . doi : 10 . 1038 / nature03866 105 . Gordon , S . Immunity 2016 , 44 , 463 – 475 . doi : 10 . 1016 / j . immuni . 2016 . 02 . 026 106 . Lim , J . P . ; Gleeson , P . A . Immunol . Cell Biol . 2011 , 89 , 836 – 843 . doi : 10 . 1038 / icb . 2011 . 20 107 . Venkataraman , S . ; Hedrick , J . L . ; Ong , Z . Y . ; Yang , C . ; Ee , P . L . R . ; Hammond , P . T . ; Yang , Y . Y . Adv . Drug Delivery Rev . 2011 , 63 , 1228 – 1246 . doi : 10 . 1016 / j . addr . 2011 . 06 . 016 108 . Lorenz , S . ; Hauser , C . P . ; Autenrieth , B . ; Weiss , C . K . ; Landfester , K . ; Mailänder , V . Macromol . Biosci . 2010 , 10 , 1034 – 1042 . doi : 10 . 1002 / mabi . 201000099 Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 351 109 . Yi , X . ; Shi , X . ; Gao , H . Phys . Rev . Lett . 2011 , 107 , 098101 . doi : 10 . 1103 / physrevlett . 107 . 098101 110 . Anselmo , A . C . ; Mitragotri , S . Adv . Drug Delivery Rev . 2016 , 108 , 51 – 67 . doi : 10 . 1016 / j . addr . 2016 . 01 . 007 111 . Niu , Y . ; Yu , M . ; Meka , A . ; Liu , Y . ; Zhang , J . ; Yang , Y . ; Yu , C . J . Mater . Chem . B 2016 , 4 , 212 – 219 . doi : 10 . 1039 / c5tb01911g 112 . Kelf , T . A . ; Sreenivasan , V . K . A . ; Sun , J . ; Kim , E . J . ; Goldys , E . M . ; Zvyagin , A . V . Nanotechnology 2010 , 21 , 285105 . doi : 10 . 1088 / 0957 - 4484 / 21 / 28 / 285105 113 . Editorial ' Time to deliver ' . Nat . Biotechnol . 2014 , 32 , 961 . doi : 10 . 1038 / nbt . 3045 114 . Akinc , A . ; Battaglia , G . Cold Spring Harbor Perspect . Biol . 2013 , 5 , a016980 . doi : 10 . 1101 / cshperspect . a016980 115 . Rejman , J . ; Oberle , V . ; Zuhorn , I . S . ; Hoekstra , D . Biochem . J . 2004 , 377 , 159 – 169 . doi : 10 . 1042 / bj20031253 116 . Lerch , S . ; Dass , M . ; Musyanovych , A . ; Landfester , K . ; Mailänder , V . Eur . J . Pharm . Biopharm . 2013 , 84 , 265 – 274 . doi : 10 . 1016 / j . ejpb . 2013 . 01 . 024 117 . Foged , C . ; Brodin , B . ; Frokjaer , S . ; Sundblad , A . Int . J . Pharm . 2005 , 298 , 315 – 322 . doi : 10 . 1016 / j . ijpharm . 2005 . 03 . 035 118 . Decuzzi , P . ; Ferrari , M . Biomaterials 2007 , 28 , 2915 – 2922 . doi : 10 . 1016 / j . biomaterials . 2007 . 02 . 013 119 . Gao , H . ; Shi , W . ; Freund , L . B . Proc . Natl . Acad . Sci . U . S . A . 2005 , 102 , 9469 – 9474 . doi : 10 . 1073 / pnas . 0503879102 120 . Chithrani , B . D . ; Ghazani , A . A . ; Chan , W . C . W . Nano Lett . 2006 , 6 , 662 – 668 . doi : 10 . 1021 / nl052396o 121 . Zauner , W . ; Farrow , N . A . ; Haines , A . M . R . J . Controlled Release 2001 , 71 , 39 – 51 . doi : 10 . 1016 / s0168 - 3659 ( 00 ) 00358 - 8 122 . Shapero , K . ; Fenaroli , F . ; Lynch , I . ; Cottell , D . C . ; Salvati , A . ; Dawson , K . A . Mol . BioSyst . 2011 , 7 , 371 – 378 . doi : 10 . 1039 / c0mb00109k 123 . Wang , S . - H . ; Lee , C . - W . ; Chiou , A . ; Wei , P . - K . J . Nanobiotechnol . 2010 , 8 , 33 . doi : 10 . 1186 / 1477 - 3155 - 8 - 33 124 . Blanco , E . ; Shen , H . ; Ferrari , M . Nat . Biotechnol . 2015 , 33 , 941 – 951 . doi : 10 . 1038 / nbt . 3330 125 . Gratton , S . E . A . ; Ropp , P . A . ; Pohlhaus , P . D . ; Luft , J . C . ; Madden , V . J . ; Napier , M . E . ; DeSimone , J . M . Proc . Natl . Acad . Sci . U . S . A . 2008 , 105 , 11613 – 11618 . doi : 10 . 1073 / pnas . 0801763105 126 . Lai , S . K . ; Hida , K . ; Man , S . T . ; Chen , C . ; Machamer , C . ; Schroer , T . A . ; Hanes , J . Biomaterials 2007 , 28 , 2876 – 2884 . doi : 10 . 1016 / j . biomaterials . 2007 . 02 . 021 127 . Agarwal , R . ; Singh , V . ; Jurney , P . ; Shi , L . ; Sreenivasan , S . V . ; Roy , K . Proc . Natl . Acad . Sci . U . S . A . 2013 , 110 , 17247 – 17252 . doi : 10 . 1073 / pnas . 1305000110 128 . Kirchhausen , T . ; Owen , D . ; Harrison , S . C . Cold Spring Harbor Perspect . Biol . 2014 , 6 , a016725 . doi : 10 . 1101 / cshperspect . a016725 129 . Fotin , A . ; Cheng , Y . ; Sliz , P . ; Grigorieff , N . ; Harrison , S . C . ; Kirchhausen , T . ; Walz , T . Nature 2004 , 432 , 573 – 579 . doi : 10 . 1038 / nature03079 130 . Saffarian , S . ; Cocucci , E . ; Kirchhausen , T . PLoS Biol . 2009 , 7 , e1000191 . doi : 10 . 1371 / journal . pbio . 1000191 131 . dos Santos , T . ; Varela , J . ; Lynch , I . ; Salvati , A . ; Dawson , K . A . Small 2011 , 7 , 3341 – 3349 . doi : 10 . 1002 / smll . 201101076 132 . dos Santos , T . ; Varela , J . ; Lynch , I . ; Salvati , A . ; Dawson , K . A . PLoS One 2011 , 6 , e24438 . doi : 10 . 1371 / journal . pone . 0024438 133 . Vercauteren , D . ; Vandenbroucke , R . E . ; Jones , A . T . ; Rejman , J . ; Demeester , J . ; De Smedt , S . C . ; Sanders , N . N . ; Braeckmans , K . Mol . Ther . 2010 , 18 , 561 – 569 . doi : 10 . 1038 / mt . 2009 . 281 134 . Herd , H . ; Daum , N . ; Jones , A . T . ; Huwer , H . ; Ghandehari , H . ; Lehr , C . - M . ACS Nano 2013 , 7 , 1961 – 1973 . doi : 10 . 1021 / nn304439f 135 . Gessner , A . ; Lieske , A . ; Paulke , B . R . ; Müller , R . H . Eur . J . Pharm . Biopharm . 2002 , 54 , 165 – 170 . doi : 10 . 1016 / s0939 - 6411 ( 02 ) 00081 - 4 136 . Fröhlich , E . Int . J . Nanomed . 2012 , 2012 , 5577 – 5591 . doi : 10 . 2147 / ijn . s36111 137 . Hühn , D . ; Kantner , K . ; Geidel , C . ; Brandholt , S . ; De Cock , I . ; Soenen , S . J . H . ; Rivera _ Gil , P . ; Montenegro , J . - M . ; Braeckmans , K . ; Müllen , K . ; Nienhaus , G . U . ; Klapper , M . ; Parak , W . J . ACS Nano 2013 , 7 , 3253 – 3263 . doi : 10 . 1021 / nn3059295 138 . Chen , L . ; Mccrate , J . M . ; Lee , J . C . - M . ; Li , H . Nanotechnology 2011 , 22 , 105708 . doi : 10 . 1088 / 0957 - 4484 / 22 / 10 / 105708 139 . Schrade , A . ; Mailänder , V . ; Ritz , S . ; Landfester , K . ; Ziener , U . Macromol . Biosci . 2012 , 12 , 1459 – 1471 . doi : 10 . 1002 / mabi . 201200166 140 . Xiao , K . ; Li , Y . ; Luo , J . ; Lee , J . S . ; Xiao , W . ; Gonik , A . M . ; Agarwal , R . G . ; Lam , K . S . Biomaterials 2011 , 32 , 3435 – 3446 . doi : 10 . 1016 / j . biomaterials . 2011 . 01 . 021 141 . Bannunah , A . M . ; Vllasaliu , D . ; Lord , J . ; Stolnik , S . Mol . Pharmaceutics 2014 , 11 , 4363 – 4373 . doi : 10 . 1021 / mp500439c 142 . Dausend , J . ; Musyanovych , A . ; Dass , M . ; Walther , P . ; Schrezenmeier , H . ; Landfester , K . ; Mailänder , V . Macromol . Biosci . 2008 , 8 , 1135 – 1143 . doi : 10 . 1002 / mabi . 200800123 143 . Harush - Frenkel , O . ; Rozentur , E . ; Benita , S . ; Altschuler , Y . Biomacromolecules 2008 , 9 , 435 – 443 . doi : 10 . 1021 / bm700535p 144 . Li , Y . ; Kröger , M . ; Liu , W . K . Nanoscale 2015 , 7 , 16631 – 16646 . doi : 10 . 1039 / c5nr02970h 145 . Carnovale , C . ; Bryant , G . ; Shukla , R . ; Bansal , V . ACS Omega 2019 , 4 , 242 – 256 . doi : 10 . 1021 / acsomega . 8b03227 146 . Qiu , Y . ; Liu , Y . ; Wang , L . ; Xu , L . ; Bai , R . ; Ji , Y . ; Wu , X . ; Zhao , Y . ; Li , Y . ; Chen , C . Biomaterials 2010 , 31 , 7606 – 7619 . doi : 10 . 1016 / j . biomaterials . 2010 . 06 . 051 147 . Chithrani , B . D . ; Chan , W . C . W . Nano Lett . 2007 , 7 , 1542 – 1550 . doi : 10 . 1021 / nl070363y 148 . Dasgupta , S . ; Auth , T . ; Gompper , G . Nano Lett . 2014 , 14 , 687 – 693 . doi : 10 . 1021 / nl403949h 149 . Huang , X . ; Teng , X . ; Chen , D . ; Tang , F . ; He , J . Biomaterials 2010 , 31 , 438 – 448 . doi : 10 . 1016 / j . biomaterials . 2009 . 09 . 060 150 . Kinnear , C . ; Moore , T . L . ; Rodriguez - Lorenzo , L . ; Rothen - Rutishauser , B . ; Petri - Fink , A . Chem . Rev . 2017 , 117 , 11476 – 11521 . doi : 10 . 1021 / acs . chemrev . 7b00194 151 . Sun , J . ; Zhang , L . ; Wang , J . ; Feng , Q . ; Liu , D . ; Yin , Q . ; Xu , D . ; Wei , Y . ; Ding , B . ; Shi , X . ; Jiang , X . Adv . Mater . ( Weinheim , Ger . ) 2015 , 27 , 1402 – 1407 . doi : 10 . 1002 / adma . 201404788 152 . Shen , Z . ; Ye , H . ; Yi , X . ; Li , Y . ACS Nano 2019 , 13 , 215 – 228 . doi : 10 . 1021 / acsnano . 8b05340 153 . Palomba , R . ; Palange , A . L . ; Rizzuti , I . F . ; Ferreira , M . ; Cervadoro , A . ; Barbato , M . G . ; Canale , C . ; Decuzzi , P . ACS Nano 2018 , 12 , 1433 – 1444 . doi : 10 . 1021 / acsnano . 7b07797 154 . Guo , P . ; Liu , D . ; Subramanyam , K . ; Wang , B . ; Yang , J . ; Huang , J . ; Auguste , D . T . ; Moses , M . A . Nat . Commun . 2018 , 9 , 130 . doi : 10 . 1038 / s41467 - 017 - 02588 - 9 155 . Anselmo , A . C . ; Zhang , M . ; Kumar , S . ; Vogus , D . R . ; Menegatti , S . ; Helgeson , M . E . ; Mitragotri , S . ACS Nano 2015 , 9 , 3169 – 3177 . doi : 10 . 1021 / acsnano . 5b00147 156 . Kuhn , D . A . ; Vanhecke , D . ; Michen , B . ; Blank , F . ; Gehr , P . ; Petri - Fink , A . ; Rothen - Rutishauser , B . Beilstein J . Nanotechnol . 2014 , 5 , 1625 – 1636 . doi : 10 . 3762 / bjnano . 5 . 174 157 . O’ Neill , M . J . ; Guo , J . ; Byrne , C . ; Darcy , R . ; O’ Driscoll , C . M . Int . J . Pharm . 2011 , 413 , 174 – 183 . doi : 10 . 1016 / j . ijpharm . 2011 . 04 . 021 Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 352 158 . Francia , V . ; Reker - Smit , C . ; Boel , G . ; Salvati , A . Nanomedicine ( London , U . K . ) 2019 , 14 , 1533 – 1549 . doi : 10 . 2217 / nnm - 2018 - 0446 159 . Francia , V . ; Aliyandi , A . ; Salvati , A . Nanoscale 2018 , 10 , 16645 – 16656 . doi : 10 . 1039 / c8nr03171a 160 . Wang , B . ; Zhang , L . ; Bae , S . C . ; Granick , S . Proc . Natl . Acad . Sci . U . S . A . 2008 , 105 , 18171 – 18175 . doi : 10 . 1073 / pnas . 0807296105 161 . Rossi , G . ; Barnoud , J . ; Monticelli , L . J . Phys . Chem . Lett . 2014 , 5 , 241 – 246 . doi : 10 . 1021 / jz402234c 162 . Zhao , W . ; Hanson , L . ; Lou , H . - Y . ; Akamatsu , M . ; Chowdary , P . D . ; Santoro , F . ; Marks , J . R . ; Grassart , A . ; Drubin , D . G . ; Cui , Y . ; Cui , B . Nat . Nanotechnol . 2017 , 12 . doi : 10 . 1038 / nnano . 2017 . 98 163 . Bahrami , A . H . ; Lipowsky , R . ; Weikl , T . R . Soft Matter 2016 , 12 , 581 – 587 . doi : 10 . 1039 / c5sm01793a 164 . Ewers , H . ; Römer , W . ; Smith , A . E . ; Bacia , K . ; Dmitrieff , S . ; Chai , W . ; Mancini , R . ; Kartenbeck , J . ; Chambon , V . ; Berland , L . ; Oppenheim , A . ; Schwarzmann , G . ; Feizi , T . ; Schwille , P . ; Sens , P . ; Helenius , A . ; Johannes , L . Nat . Cell Biol . 2010 , 12 , 11 – 18 . doi : 10 . 1038 / ncb1999 165 . Xu , M . ; Soliman , M . G . ; Sun , X . ; Pelaz , B . ; Feliu , N . ; Parak , W . J . ; Liu , S . ACS Nano 2018 , 12 , 10104 – 10113 . doi : 10 . 1021 / acsnano . 8b04906 166 . Leong , H . S . ; Butler , K . S . ; Brinker , C . J . ; Azzawi , M . ; Conlan , S . ; Dufés , C . ; Owen , A . ; Rannard , S . ; Scott , C . ; Chen , C . ; Dobrovolskaia , M . A . ; Kozlov , S . V . ; Prina - Mello , A . ; Schmid , R . ; Wick , P . ; Caputo , F . ; Boisseau , P . ; Crist , R . M . ; McNeil , S . E . ; Fadeel , B . ; Tran , L . ; Hansen , S . F . ; Hartmann , N . B . ; Clausen , L . P . W . ; Skjolding , L . M . ; Baun , A . ; Ågerstrand , M . ; Gu , Z . ; Lamprou , D . A . ; Hoskins , C . ; Huang , L . ; Song , W . ; Cao , H . ; Liu , X . ; Jandt , K . D . ; Jiang , W . ; Kim , B . Y . S . ; Wheeler , K . E . ; Chetwynd , A . J . ; Lynch , I . ; Moghimi , S . M . ; Nel , A . ; Xia , T . ; Weiss , P . S . ; Sarmento , B . ; das Neves , J . ; Santos , H . A . ; Santos , L . ; Mitragotri , S . ; Little , S . ; Peer , D . ; Amiji , M . M . ; Alonso , M . J . ; Petri - Fink , A . ; Balog , S . ; Lee , A . ; Drasler , B . ; Rothen - Rutishauser , B . ; Wilhelm , S . ; Acar , H . ; Harrison , R . G . ; Mao , C . ; Mukherjee , P . ; Ramesh , R . ; McNally , L . R . ; Busatto , S . ; Wolfram , J . ; Bergese , P . ; Ferrari , M . ; Fang , R . H . ; Zhang , L . ; Zheng , J . ; Peng , C . ; Du , B . ; Yu , M . ; Charron , D . M . ; Zheng , G . ; Pastore , C . Nat . Nanotechnol . 2019 , 14 , 629 – 635 . doi : 10 . 1038 / s41565 - 019 - 0496 - 9 167 . Lammers , T . ; Storm , G . Nat . Nanotechnol . 2019 , 14 , 626 . doi : 10 . 1038 / s41565 - 019 - 0497 - 8 168 . Sahay , G . ; Querbes , W . ; Alabi , C . ; Eltoukhy , A . ; Sarkar , S . ; Zurenko , C . ; Karagiannis , E . ; Love , K . ; Chen , D . ; Zoncu , R . ; Buganim , Y . ; Schroeder , A . ; Langer , R . ; Anderson , D . G . Nat . Biotechnol . 2013 , 31 , 653 – 658 . doi : 10 . 1038 / nbt . 2614 169 . Pangarkar , C . ; Dinh , A . - T . ; Mitragotri , S . J . Controlled Release 2012 , 162 , 76 – 83 . doi : 10 . 1016 / j . jconrel . 2012 . 05 . 022 170 . Behr , J . Chimia 1997 , 51 , 34 – 36 . 171 . Rehman , Z . u . ; Hoekstra , D . ; Zuhorn , I . S . ACS Nano 2013 , 7 , 3767 – 3777 . doi : 10 . 1021 / nn3049494 172 . El - Sayed , A . ; Futaki , S . ; Harashima , H . AAPS J . 2009 , 11 , 13 – 22 . doi : 10 . 1208 / s12248 - 008 - 9071 - 2 173 . Krpeti ć , Ž . ; Saleemi , S . ; Prior , I . A . ; Sée , V . ; Qureshi , R . ; Brust , M . ACS Nano 2011 , 5 , 5195 – 5201 . doi : 10 . 1021 / nn201369k 174 . Chou , L . Y . T . ; Ming , K . ; Chan , W . C . W . Chem . Soc . Rev . 2011 , 40 , 233 – 245 . doi : 10 . 1039 / c0cs00003e 175 . Varkouhi , A . K . ; Scholte , M . ; Storm , G . ; Haisma , H . J . J . Controlled Release 2011 , 151 , 220 – 228 . doi : 10 . 1016 / j . jconrel . 2010 . 11 . 004 176 . Martens , T . F . ; Remaut , K . ; Demeester , J . ; De Smedt , S . C . ; Braeckmans , K . Nano Today 2014 , 9 , 344 – 364 . doi : 10 . 1016 / j . nantod . 2014 . 04 . 011 177 . Smith , S . A . ; Selby , L . I . ; Johnston , A . P . R . ; Such , G . K . Bioconjugate Chem . 2019 , 30 , 263 – 272 . doi : 10 . 1021 / acs . bioconjchem . 8b00732 178 . Chai , G . - H . ; Hu , F . - Q . ; Sun , J . ; Du , Y . - Z . ; You , J . ; Yuan , H . Mol . Pharmaceutics 2014 , 11 , 3716 – 3726 . doi : 10 . 1021 / mp5004674 179 . Ghaffarian , R . ; Bhowmick , T . ; Muro , S . J . Controlled Release 2012 , 163 , 25 – 33 . doi : 10 . 1016 / j . jconrel . 2012 . 06 . 007 180 . Rezaei , G . ; Daghighi , S . M . ; Haririan , I . ; Yousefi , I . ; Raoufi , M . ; Rezaee , F . ; Dinarvand , R . Colloids Surf . , B 2019 , 179 , 505 – 516 . doi : 10 . 1016 / j . colsurfb . 2019 . 04 . 003 181 . Krug , H . F . Angew . Chem . , Int . Ed . 2014 , 53 , 12304 – 12319 . doi : 10 . 1002 / anie . 201403367 182 . Haase , A . ; Lynch , I . NanoImpact 2018 , 11 , 67 – 68 . doi : 10 . 1016 / j . impact . 2018 . 02 . 005 183 . Editorial ' Join the , dialogue ' . Nat . Nanotechnol . 2012 , 7 , 545 . doi : 10 . 1038 / nnano . 2012 . 150 184 . Malcolm , D . W . ; Varghese , J . J . ; Sorrells , J . E . ; Ovitt , C . E . ; Benoit , D . S . W . ACS Nano 2018 , 12 , 187 – 197 . doi : 10 . 1021 / acsnano . 7b05528 185 . Lazzari , S . ; Moscatelli , D . ; Codari , F . ; Salmona , M . ; Morbidelli , M . ; Diomede , L . J . Nanopart . Res . 2012 , 14 , 920 . doi : 10 . 1007 / s11051 - 012 - 0920 - 7 186 . Lesniak , A . ; Fenaroli , F . ; Monopoli , M . P . ; Åberg , C . ; Dawson , K . A . ; Salvati , A . ACS Nano 2012 , 6 , 5845 – 5857 . doi : 10 . 1021 / nn300223w 187 . Kim , J . A . ; Salvati , A . ; Åberg , C . ; Dawson , K . A . Nanoscale 2014 , 6 , 14180 – 14184 . doi : 10 . 1039 / c4nr04970e 188 . Mazzolini , J . ; Weber , R . J . M . ; Chen , H . - S . ; Khan , A . ; Guggenheim , E . ; Shaw , R . K . ; Chipman , J . K . ; Viant , M . R . ; Rappoport , J . Z . Biol . Bull . ( Woods Hole , MA , U . S . ) 2016 , 231 , 40 – 60 . doi : 10 . 1086 / 689590 189 . Digiacomo , L . ; Cardarelli , F . ; Pozzi , D . ; Palchetti , S . ; Digman , M . A . ; Gratton , E . ; Capriotti , A . L . ; Mahmoudi , M . ; Caracciolo , G . Nanoscale 2017 , 9 , 17254 – 17262 . doi : 10 . 1039 / c7nr06437c 190 . Voigt , J . ; Christensen , J . ; Shastri , V . P . Proc . Natl . Acad . Sci . U . S . A . 2014 , 111 , 2942 – 2947 . doi : 10 . 1073 / pnas . 1322356111 191 . Hild , W . ; Pollinger , K . ; Caporale , A . ; Cabrele , C . ; Keller , M . ; Pluym , N . ; Buschauer , A . ; Rachel , R . ; Tessmar , J . ; Breunig , M . ; Goepferich , A . Proc . Natl . Acad . Sci . U . S . A . 2010 , 107 , 10667 – 10672 . doi : 10 . 1073 / pnas . 0912782107 192 . Lunov , O . ; Syrovets , T . ; Loos , C . ; Beil , J . ; Delacher , M . ; Tron , K . ; Nienhaus , G . U . ; Musyanovych , A . ; Mailänder , V . ; Landfester , K . ; Simmet , T . ACS Nano 2011 , 5 , 1657 – 1669 . doi : 10 . 1021 / nn2000756 193 . Al Soraj , M . ; He , L . ; Peynshaert , K . ; Cousaert , J . ; Vercauteren , D . ; Braeckmans , K . ; De Smedt , S . C . ; Jones , A . T . J . Controlled Release 2012 , 161 , 132 – 141 . doi : 10 . 1016 / j . jconrel . 2012 . 03 . 015 194 . Choi , H . S . ; Ashitate , Y . ; Lee , J . H . ; Kim , S . H . ; Matsui , A . ; Insin , N . ; Bawendi , M . G . ; Semmler - Behnke , M . ; Frangioni , J . V . ; Tsuda , A . Nat . Biotechnol . 2010 , 28 , 1300 – 1303 . doi : 10 . 1038 / nbt . 1696 195 . Barrán - Berdón , A . L . ; Pozzi , D . ; Caracciolo , G . ; Capriotti , A . L . ; Caruso , G . ; Cavaliere , C . ; Riccioli , A . ; Palchetti , S . ; Laganà , A . Langmuir 2013 , 29 , 6485 – 6494 . doi : 10 . 1021 / la401192x 196 . Casals , E . ; Pfaller , T . ; Duschl , A . ; Oostingh , G . J . ; Puntes , V . ACS Nano 2010 , 4 , 3623 – 3632 . doi : 10 . 1021 / nn901372t 197 . Lundqvist , M . ; Stigler , J . ; Cedervall , T . ; Berggård , T . ; Flanagan , M . B . ; Lynch , I . ; Elia , G . ; Dawson , K . ACS Nano 2011 , 5 , 7503 – 7509 . doi : 10 . 1021 / nn202458g Beilstein J . Nanotechnol . 2020 , 11 , 338 – 353 . 353 198 . Liu , R . ; Jiang , W . ; Walkey , C . D . ; Chan , W . C . W . ; Cohen , Y . Nanoscale 2015 , 7 , 9664 – 9675 . doi : 10 . 1039 / c5nr01537e 199 . Kelly , P . M . ; Åberg , C . ; Polo , E . ; O’Connell , A . ; Cookman , J . ; Fallon , J . ; Krpeti ć , Ž . ; Dawson , K . A . Nat . Nanotechnol . 2015 , 10 , 1 – 8 . doi : 10 . 1038 / nnano . 2015 . 47 200 . Fujimoto , T . ; Kogo , H . ; Nomura , R . ; Une , T . J . Cell Sci . 2000 , 113 , 3509 – 3517 . 201 . Schimpel , C . ; Teubl , B . ; Absenger , M . ; Meindl , C . ; Fröhlich , E . ; Leitinger , G . ; Zimmer , A . ; Roblegg , E . Mol . Pharmaceutics 2014 , 11 , 808 – 818 . doi : 10 . 1021 / mp400507g 202 . Gamboa , J . M . ; Leong , K . W . Adv . Drug Delivery Rev . 2013 , 65 , 800 – 810 . doi : 10 . 1016 / j . addr . 2013 . 01 . 003 203 . Costa , E . C . ; Gaspar , V . M . ; Marques , J . G . ; Coutinho , P . ; Correia , I . J . PLoS One 2013 , 8 , e70072 . doi : 10 . 1371 / journal . pone . 0070072 204 . Mayor , S . ; Parton , R . G . ; Donaldson , J . G . Cold Spring Harbor Perspect . Biol . 2014 , 6 , a016758 . doi : 10 . 1101 / cshperspect . a016758 205 . Harding , C . ; Heuser , J . ; Stahl , P . J . Cell Biol . 1983 , 97 , 329 – 339 . doi : 10 . 1083 / jcb . 97 . 2 . 329 206 . Vasile , E . ; Simionescu , M . ; Simionescu , N . J . Cell Biol . 1983 , 96 , 1677 – 1689 . doi : 10 . 1083 / jcb . 96 . 6 . 1677 207 . Marks , D . L . ; Singh , R . D . ; Choudhury , A . ; Wheatley , C . L . ; Pagano , R . E . Methods 2005 , 36 , 186 – 195 . doi : 10 . 1016 / j . ymeth . 2004 . 12 . 001 208 . Lajoie , P . ; Kojic , L . D . ; Nim , S . ; Li , L . ; Dennis , J . W . ; Nabi , I . R . J . Cell . Mol . Med . 2009 , 13 , 3218 – 3225 . doi : 10 . 1111 / j . 1582 - 4934 . 2009 . 00732 . x 209 . Torgersen , M . L . ; Skretting , G . ; van Deurs , B . ; Sandvig , K . J . Cell Sci . 2001 , 114 , 3737 – 3747 . 210 . Damm , E . - M . ; Pelkmans , L . ; Kartenbeck , J . ; Mezzacasa , A . ; Kurzchalia , T . ; Helenius , A . J . Cell Biol . 2005 , 168 , 477 – 488 . doi : 10 . 1083 / jcb . 200407113 211 . Schliwa , M . J . Cell Biol . 1982 , 92 , 79 – 91 . doi : 10 . 1083 / jcb . 92 . 1 . 79 212 . Yarar , D . ; Waterman - Storer , C . M . ; Schmid , S . L . Mol . Biol . Cell 2005 , 16 , 964 – 975 . doi : 10 . 1091 / mbc . e04 - 09 - 0774 213 . Ivanov , A . I . Pharmacological Inhibition of Endocytic Pathways : Is It Specific Enough to Be Useful ? . In Exocytosis and Endocytosis ; Ivanov , A . I . , Ed . ; Methods in Molecular Biolog , Vol . 440 ; 2008 ; pp 15 – 33 . doi : 10 . 1007 / 978 - 1 - 59745 - 178 - 9 _ 2 214 . Hayer , A . ; Stoeber , M . ; Ritz , D . ; Engel , S . ; Meyer , H . H . ; Helenius , A . J . Cell Biol . 2010 , 191 , 615 – 629 . doi : 10 . 1083 / jcb . 201003086 215 . Roberts , B . ; Haupt , A . ; Tucker , A . ; Grancharova , T . ; Arakaki , J . ; Fuqua , M . A . ; Nelson , A . ; Hookway , C . ; Ludmann , S . A . ; Mueller , I . A . ; Yang , R . ; Horwitz , R . ; Rafelski , S . M . ; Gunawardane , R . N . Mol . Biol . Cell 2017 , 28 , 2854 – 2874 . doi : 10 . 1091 / mbc . e17 - 03 - 0209 216 . Khan , A . O . ; Simms , V . A . ; Pike , J . A . ; Thomas , S . G . ; Morgan , N . V . Sci . Rep . 2017 , 7 , 8450 . doi : 10 . 1038 / s41598 - 017 - 08493 - x 217 . Wittrup , A . ; Zhang , S . - H . ; Svensson , K . J . ; Kucharzewska , P . ; Johansson , M . C . ; Morgelin , M . ; Belting , M . Proc . Natl . Acad . Sci . U . S . A . 2010 , 107 , 13342 – 13347 . doi : 10 . 1073 / pnas . 1002622107 218 . Yau , E . H . ; Rana , T . M . Methods Mol . Biol . ( N . Y . , NY , U . S . ) 2018 , 1712 , 203 – 216 . doi : 10 . 1007 / 978 - 1 - 4939 - 7514 - 3 _ 13 219 . Gosney , J . A . ; Wilkey , D . W . ; Merchant , M . L . ; Ceresa , B . P . J . Biol . Chem . 2018 , 293 , 5895 – 5908 . doi : 10 . 1074 / jbc . ra117 . 000632 License and Terms This is an Open Access article under the terms of the Creative Commons Attribution License ( https : / / creativecommons . org / licenses / by / 4 . 0 ) . Please note that the reuse , redistribution and reproduction in particular requires that the authors and source are credited . The license is subject to the Beilstein Journal of Nanotechnology terms and conditions : ( https : / / www . beilstein - journals . org / bjnano ) The definitive version of this article is the electronic one which can be found at : doi : 10 . 3762 / bjnano . 11 . 25